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ABSTRACT OF THE DISSERTATION 
Genetic and Epigenetic Interactions in in vivo and in vitro Reprogramming 
by 
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Professor Timothy Ley, Chairperson 
 
In cancer pathogenesis and induced pluripotent stem (iPS) cell production, an essential 
step for reprogramming is acquisition of self-renewal. In hematopoietic cells, HOX genes 
are partially responsible for self-renewal, and HOX gene dysregulation commonly occurs 
in acute myeloid leukemia (AML). HOX dysregulation is seen in AML with 
translocations involving HOX genes themselves (e.g. NUP98-HOXA9) and with other 
disease-initiating translocations (e.g. MLL translocations and inv(16)).  However, HOX 
genes are also highly expressed in many AML samples without translocations; the 
mechanism that causes “dysregulation” in these cases is unknown. Whole genome 
sequencing of 45 de novo AML genomes showed that recurrent mutations in the HOX 
gene clusters are not responsible for the phenotype. Expression array data from 190 AML 
cases revealed that while translocations have unique HOX expression patterns, most 
AML cases predominantly express HOXA5, A9, A10, B2, B3, and MEIS1 in a canonical, 
highly coordinated pattern that is virtually identical to that found in normal human CD34 
	   xi	  
cells. HOX gene “dysregulation” in these cases may therefore represent the persistence of 
a normal, stem cell-specific HOX gene expression pattern that is probably required for 
self-renewal, and “captured” by mutations that initiate leukemia in hematopoietic stem 
cells. 
In vitro reprogramming induces self-renewal with overexpression of a cocktail of 
transcription factors, often in the form of integrating viruses, which have raised concerns 
about the genomic integrity of iPS lines. We performed whole genome sequencing of 10 
murine iPS lines produced in 3 independent experiments. We found an average of 414 
somatic nucleotide variants (SNVs) per iPS clone, with variant allele frequencies 
suggesting that the mutations occurred at or before reprogramming. In one experiment, 
four independent iPS clones contained 164 identical variants (6 protein-coding SNVs, 
157 non-coding SNVs and 1 structural variant) that were also found in rare parental cells, 
suggesting that these rare cells were extraordinarily “fit” for reprogramming. Our data 
suggest that most of the mutations detected in iPS cells occurred prior to reprogramming 
and are simply “captured” by cloning; however, some preexisting mutations provide an 
advantage for reprogramming, and may provide novel insights into the genetic 
underpinnings of this process. 
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Chapter 1 
 
 
 
Introduction 
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1.1 Development and reprogramming of somatic cells 
In developmental biology, differentiation is the process of stem and progenitor cells 
evolving to generate all of the cell types of an organism. In this physiological setting, 
differentiation is generally a unidirectional process. The hematopoietic system can be 
used as an example of a well-studied differentiation pathway. All hematopoietic cells are 
generated from a single pool of hematopoietic stem cells (HSCs). Activating different 
transcription factors allows progenitors to become lymphoid (B, T and NK cells), 
myeloid (macrophages, neutrophils), erythrocytes, or megakaryocytes. These cell fate 
decisions are typically irreversible. This can be illustrated by development of T cells. The 
common lymphoid progenitor (CLP) is able to generate both B and T cells, and expresses 
the Notch receptor.  When the CLP enters the thymus, it encounters its ligand, Jagged, 
activating Notch signaling [1]. Activated Notch not only promotes T cell development, 
but also blocks B cell development, ensuring that once a cell commits to being a T cell; it 
cannot convert to a B cell. Experimentally this can be seen as thymocyte deficiency in 
inactivated Notch models [2]. Conversely, B cell deficiency occurs in models of 
constitutively active Notch [3]. Cellular “reprogramming” involves manipulating cells to 
override the normal one-way process of development to generate stem cells from fully 
differentiated somatic cells. 
 In a living organism a process similar to reprogramming can sometimes lead to cancer. 
Oncogenic mutations are thought to allow a differentiated cell to take on the stem cell 
characteristic of self-renewal that can lead to the unchecked growth of a tumor.  This 
reprogrammed cell is sometimes called a cancer stem cell (CSC). It is still unclear 
whether the CSC is a product of a differentiated cell being transformed to a stem cell, or 
	   3	  
if an existing stem cell is altered to lose its normal growth restrictions to become 
transformed. Most likely, both scenarios occur.   
In 2006, Yamanaka, et al. published the first report of in vitro reprogramming in mouse 
cells. By overexpressing a cocktail of factors (Oct4, Sox2, Klf4 and c-Myc) in fibroblasts, 
his laboratory was able to generate cells with an embryonic stem (ES) cell-like 
phenotype, which they named induced pluripotent stem (iPS) cells [4]. A year later, 
human iPS cells were reported using the same factors by Yamanaka’s group;  a second 
group, lead by James Thomson, generated human iPS cells with a slightly different 
cocktail (OCT3/4, SOX 2, NANOG and LIN28) [5, 6]. Highlighting the relationship 
between this in vitro reprogramming and the in vivo reprogramming of oncogenesis is the 
fact that iPS cells are tested for pluripotency by defining their ability to form teratomas in 
immune-deficient mice [4-6].  The mechanism behind both types of reprogramming is 
still not understood. To determine how a cell can be manipulated to become a new cell 
type, first one has to know what determines cell identity and fate. 
Identity is defined at the organismal and cellular levels by genetics. Unique combinations 
of single nucleotide polymorphisms (SNPs) create diversity and distinguish one person 
from the next. But within a single person there are hundreds of different cell types. Each 
of these cells contains the same genetic information, yet they are able to perform distinct 
functions. These cell fate decisions are determined by epigenetic factors. The term 
epigenetics refers to any alteration of DNA that does not involve a permanent change in 
the actual nucleotide sequence. The two main layers of epigenetics are DNA methylation 
and histone modifications. The main consequences of these changes are alterations in 
gene expression. Epigenetic changes can be heritable, but unlike genomic changes, they 
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are also reversible (which can be seen in reprogramming). Since cell identity and fate is 
determined by a combination of both the genome and epigenome, it follows that 
alterations in either can have detrimental effects, such as oncogenic transformation.  
1.2. Acute Myeloid Leukemia: A model of “in vivo reprogramming” 
Acute myeloid leukemia (AML) is a heterogeneous group of diseases at the level of 
morphology, molecular lesions and prognosis. Strategies have been designed to stratify 
AML into groups that can help classify patients for therapy and prognosis. The French-
American-British (FAB) classification system was developed over thirty years ago, and 
classifies AML (based on classic morphological characteristics) into 8 subtypes MO-M7 
[7]. While FAB categories overlap some with cytogenetics (nearly all M3 or acute 
promyelocytic leukemia (APL) cases harbor the (15;17) translocation, for example), the 
World Health Organization (WHO) has created a more clinically useful classification 
scheme (AML with cytogenetic abnormalities, AML with a prior dysplasia, therapy 
related AML and “other AML” that does not fall into one of the previous categories)[8]. 
The variability of AML can be used to illustrate the different types of genetic alterations 
involved in cancer pathogenesis- point mutations, translocations and insertions/deletions.  
1.2.1. Reprogramming translocations in AML 
Recurrent translocations are currently the most useful marker for prognosis within AML. 
Translocations are large-scale chromosomal abnormalities, which can be visualized with 
low-resolution studies such as karyotyping and fluorescence in situ hybridization (FISH). 
Double-strand DNA breaks that occur throughout the genome are normally repaired by 
joining the adjacent regions back together with no loss of genomic integrity. However, if 
there are multiple double stranded breaks present in the genome at the same time, it is 
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possible to swap the chromosomes during the repair process, which leads to 
translocations.  
As mentioned above, a translocation between chromosomes 15 and 17 is the defining 
factor of APL. This translocation creates a fusion protein involving the retinoic acid 
receptor alpha (RARα) and the promyelocytic leukemia gene (PML) to generate the 
novel PML-RARα protein [9]. Both PML and RARα contain DNA-binding motifs that 
are retained in the fusion protein and are thought to define a distinct set of target genes 
for PML-RARα [10]. Mouse models have been critical in defining PML-RARα as the 
initiating event in APL. The first mouse model of APL was created by expressing the 
PML-RARα fusion protein under the control of the human cathepsin G regulatory 
sequences (hCG-PR) to target expression to the promyelocyte compartment by the Ley 
laboratory and was subsequently confirmed by the Pandolfi group [11, 12]. While hCG-
PR mice do develop leukemia, there is a latency of approximately 220 days with low 
penetrance (15 percent) [11]. The penetrance was increased to greater than 90 percent by 
knocking PML-RARα into the endogenous murine CG locus [13]. Co-expression of 
additional oncogenes (including activated FLT3, Bcl2 and activated K-ras) are able to 
increase the penetrance in the hCG- PML-RARα transgenic mouse [14-16]. This data, 
along with the finding of additional recurrent chromosomal abnormalities in APL mice, 
suggest that while PML-RARα is sufficient as an initiating event, progression hits are 
required for full leukemic transformation [17]. Another important effect of translocations 
causing fusion proteins is the reciprocal haploinsufficiency of the fusion partners which 
could also have pathogenic effects, although these are modest in the case of t(15,17) [18]. 
While the leukemogenic mechanism of these fusion proteins is not fully understood, 
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some have a favorable effect on prognosis [19]. In the case of patients with t(15;17), this 
is because all-trans retinoic acid is a highly effective, targeted therapy [20-24].  
One of the most common translocations in AML involves chromosomes 8 and 21, 
causing a fusion protein of AML1 and ETO. AML1 is a subunit of the core binding factor 
(CBF) transcription factor; the β unit of CBF is involved in another common AML 
translocation inv(16) where it creates a fusion protein with the myosin heavy chain gene, 
MYH11. These novel CBF fusion proteins alter the activity of the transcription factor, 
but mechanisms of transformation are not fully understood [19, 25, 26]. Knock-in mouse 
models of AML1-ETO are embryonic lethal, [27, 28] so conditional models have been 
used to study the leukemogenic capacity of the fusion protein [29-31]. By expressing 
AML1-ETO via the Sca1 locus (targeting to the hematopoietic stem cell compartment), 
heterozygous HSCs showed increased survival in vitro, and the mice developed a 
myeloproliferative disorder [31]. Myeloid-lineage expression (including common 
myeloid progenitors) of AML1-ETO did not lead to malignancy on its own, but treatment 
with a DNA-alkylating mutagen was able to skew AML1-ETO expressing cells to 
myeloid leukemia, as opposed to lymphoblastic leukemia in their wildtype littermates 
[29]. Similar to PML-RARα, AML1-ETO acts as an initiating mutation, but requires 
additional progressive mutations to develop leukemia (such as Flt3 and c-Kit mutations) 
[32, 33]. AML1-ETO translocations are also similar to t(15;17), in that they predict a 
favorable outcome [34]. 
In contrast, translocations involving the mixed lineage leukemia (MLL) gene on 
chromosome 11 confer a poor prognosis [35, 36]. There are more than fifty fusion 
partners involved in MLL translocations. In 1997, a group lead by Terrence Rabbits 
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showed that chimeric mice produced by injecting blastocysts with embryonic stem (ES) 
cells engineered with an MLL-AF9 fusion developed leukemia starting at 4 months, with 
most mice dying by one year. Interestingly, even though the animals showed widespread 
activity of the MLL promoter, tumors were restricted to the myeloid compartment [37]. 
Using mice heterozygous for the MLL-AF9 fusion (homozygous expression is embryonic 
lethal) the same group found that AML in these animals is preceded by 
myeloproliferation, indicating that, like the other reprogramming translocations, 
additional mutations are necessary to develop frank leukemia [38]. Using a retroviral 
system with bone marrow transplant, Armstrong’s group proved that FLT3-ITD 
cooperates with MLL-AF9, decreasing latency from ~70 days to 30 days [39]. In addition 
to translocations, MLL can also have a “partial tandem duplication” mutation. While this 
is often associated with trisomy 11, there are also cases of normal karyotype MLL-PTD 
[40, 41]. The main molecular consequence of MLL fusions is thought to be 
overexpression of HOX genes [42, 43]. This association along with HOX expression in 
normal karyotype AML is explored in Chapter 2. 
1.2.2. Recurrent mutations in AML 
With advances in molecular techniques, there are now a handful of recurrent point 
mutations associated with AML. A point mutation refers to changing a single nucleotide; 
these mutations can be classified as missense, nonsense or silent. A silent mutation either 
falls within a non-coding region of DNA, or if within an exon, does not alter the amino 
acid sequence (e.g. codons AAA and AAG both code for lysine), and is generally 
considered to be innocuous. However, silent mutations that fall within regulatory 
sequences, such as splice site acceptor or donor sites, can have detrimental effects even 
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though they do not fall within a coding sequence. A missense mutation, however, 
changes the corresponding amino acid, which may or may not drastically alter protein 
function (e.g. the mutation that causes sickle cell anemia is an A to T substitution that 
changes a glutamic acid residue to valine). A nonsense mutation changes a coding triplet 
to a premature stop codon (e.g. C to T substitution changes the codon CGA (arginine) to 
TGA (STOP)), which can then create a truncated protein that may be non-functional, 
dominant negative, or cause nonsense mediated decay. One of the most common (4-7% 
of cases) point mutations seen in AML is in the protein kinase domain of the fms-related 
tyrosine kinase 3 (FLT3-TKD) [44, 45]. The mutation is at residue 835 within the 
activation loop of the kinase domain and causes the protein to be constitutively active 
even in the absence of ligand [46]. More recently, mutations in DNA methyltransferase 
3A (DNMT3A) were shown to be present in 22% of AML patients [47, 48]; the most 
common mutation falls within the methyltransferase domain at residue 882. Both FLT3 
and DNMT3A point mutations predict a poor prognosis [47, 49-52].  
Copy number variations (CNVs) are generated by the addition or deletion of nucleotides. 
Insertions and deletions cover the full spectrum from a single nucleotide to large blocks 
of sequence (megabases). Smaller CNVs are called “indels” and once again, FLT3 
provides an example of this genetic aberration seen in AML. Even more common than 
point mutations within the activation loop of FLT3 are internal tandem duplications 
within the juxtamembrane domain of the protein (FLT3-ITD). FLT3-ITDs are a 
heterogeneous set of mutations with the length and position of the duplication being 
variable. FLT3-ITD mutations lead to a constitutively active kinase and a poor prognosis 
for the patient [53, 54]. FLT3 and DNMT3A mutations are often found in conjunction 
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with mutations in the nucleophosmin (NPM1) gene [55]. Virtually all mutations in NPM1 
induce frame shifts that change the C-terminal amino acid sequence, causing a change in 
the distribution pattern of the protein (from nuclear to cytoplasmic) [55]. Mutations in the 
transcription factor CCAAT/enhancer binding protein alpha (C/EBP α) involved in 
myeloid differentiation and proliferation are seen in 7-10% of de novo AML cases and 
are comprised of all types of mutations- for example, 3-bp deletions and 3- or 15- bp 
duplications that cause in-frame alterations, as well as a nonsense point mutation at 
residue 284 [56]. These mutations have been shown to cause loss-of-function; on their 
own, CEBPA mutations are associated with favorable outcome [57, 58]. 
Larger CNVs allow for deletion or duplication of an entire gene or set of genes. 
Generally, tumor suppressor genes are involved in deletions and oncogenes are 
duplicated. A common chromosomal loss seen in AML (and myelodysplastic syndrome- 
MDS) is del(5q), where all or part of the long arm of chromosome 5 is deleted. While the 
borders of the deleted region are variable, there are commonly deleted regions (CDRs). 
There are multiple putative tumor-suppressor genes within these CDRs, including RPS14 
(a ribosomal subunit necessary for translation) and α-catenin (cytoskeletal remodeling 
protein) [59, 60]. Matt Walter’s group analyzed knockdown of another gene that falls 
within del(5q3.2), HSPA9, in human primary hematopoietic cells and murine bone 
marrow transplant experiments. In the mouse model, there was a significant decrease in 
multiple lineages including hematopoietic progenitors; in human cells defects were 
limited to delayed maturation of erythroid cells and decreased cell growth. These results 
show that while HSPA9 haploinsufficiency is not leukemogenic on its own, it does 
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contribute to abnormal hematopoiesis [61]. Large deletions could be a less specific way 
to target multiple cooperative tumor-suppressors at once. 
While these mutation types have been discussed as individual events, oncogenesis is 
thought to be a progressive process, and cancer cells harbor multiple genetic lesions of 
various mutation types. By gradually learning more about the mutational landscape of 
cancer, we can better understand the mechanisms of oncogenesis. 
1.3. The epigenetic landscape 
1.3.1. DNA methylation 
In addition to genetic changes, alterations in epigenetic signatures are thought to alter 
gene expression and play a role in cancer progression. Epigenetic modification of the 
genome is normal; changing normal patterns is what can be pathogenic. The epigenetic 
landscape is much more complicated than the straightforward four base pair code that 
defines the genome. There are multiple layers of epigenetic modifications that are able to 
interact to regulate gene expression. Here, I will focus on the two main forms of 
epigenetic modifications: DNA methylation and histone modifications. DNA methylation 
is addition of a methyl side group to the 5 position of the pyrimidine ring of nucleotides 
(most commonly the cytosine residue of a CpG dinucleotide). DNA methyltransferases 
(DNMTs) are the proteins responsible for methylation. DNMT1 is a maintenance 
enzyme, while DNMT3A and DNMT3B are de novo methyltransferases. While 
underrepresented in the genome, CpG dinucleotides are concentrated in gene promoters 
as well as CpG islands. Methylation at promoters can act as a repressive signal for gene 
expression. Recent work has shown that gene expression is also affected by intragenic 
methylation [62]. As opposed to promoter methylation, intragenic methylation can be a 
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positive signal for expression. Many tumors show an overall hypomethylation phenotype, 
with focal hypermethylation at key promoters [63, 64].  
The original methylation hypothesis suggested that hypomethylation caused loss of 
repression of oncogenes. However, it is now appreciated that there are at least three 
oncogenic mechanisms enabled by hypomethylation: 1) chromosomal instability, 2) loss 
of imprinting and 3) reactivation of transposable elements. A decrease in methylation 
creates chromosomal instability by favoring mitotic recombination, which can lead to 
translocations and loss of heterozygosity (important for loss of tumor suppressor 
expression in cancer cells). Hypomethylation in centromeric regions can lead to 
aneuploidy, another common feature of malignant cells. Imprinting is an inherited 
epigenetic mark that leads to mono-allelic expression of certain genes. Two imprinted 
genes on chromosome 11 are affected by global hypomethylation in cancer samples: H19 
and IGF-2. A decrease in methylation can lead to overexpression of the anti-apoptotic 
growth factor (IGF-2) and loss of a transformation-suppressing RNA, H19, in some 
childhood cancers [65]. Lastly, hypermethylation is a technique that human cells use to 
silence parasitic sequences that have integrated into the genome. These parasitic elements 
can act as transposons when expressed, inserting into novel sites and disrupting normal 
gene expression. Howard, et al. used a mouse model of hypomethylation to show that 
methylation status affected transposition of endogenous retroviral sequences. The 
hypomethylated genomes had transposons inserted into the Notch1 locus, which led to 
oncogenic activation of the gene [66]. There are some examples of hypomethylation of an 
oncogene contributing to cancer by increasing expression. The multidrug resistance gene 
(MDR1) was shown to have an inverse relationship between its promoter’s methylation 
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and its expression level [67]. While this alteration would not initiate cancer, it could have 
important affects on drug effectiveness for some affected patients. 
Focal hypermethylation of promoters of tumor suppressors, however, is a recurrent 
observation in malignancies. The cyclin-dependent kinase inhibitor p15 (CDKN2B) is a 
tumor suppressor frequently altered in many cancers. While deletions of p15 are common 
in acute lymphoblastic leukemia (ALL), deletions and mutations of p15 are rare in AML. 
Instead, inactivation of p15 in AML is achieved by hypermethylation of the p15 promoter 
[68-71]. In one study, 88% of adult AML patients showed p15 promoter 
hypermethylation [70]. Another group showed that hypermethyation is associated with 
poor prognosis, but this has not been confirmed in additional studies [71].  
DNA methylation can also indirectly cause genetic aberrations, revealing an interplay of 
genetics and epigenetics. Methylated cytosine residues undergo spontaneous 
deamination, which changes the cytosine to a thymine, a transition mutation. The 
APOBEC family of enzymes can also catalyze this deamination [72]. AID (activation-
induced cytidine deaminase) is a member of the APOBEC family, which is responsible 
for generating antibody diversity by creating mutations within the lymphocyte receptor 
genes. Inappropriate expression of AID, however, has been shown to be oncogenic in 
some systems [73-77].  
1.3.2. Histone Modifications 
In cells, DNA is wrapped around histones to form chromatin. Histones are octomeric 
complexes composed of four proteins (H2A, H2B, H3 and H4: 2 subunits of each). The 
amino-terminal tail of each protein is exposed. Lysine residues on the tails of H3 and H4 
can be acetylated or methylated to affect chromatin structure and gene expression. Lysine 
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methyltransferases (HMTs) are specific to a single lysine residue. For example, the 
enzyme EZH2 methylates H3K27, while MLL1 acts on H3K4. There are also histone 
demethylases (HDMs) that remove methyl groups, allowing histone modification to be a 
dynamic process [78]. Similar to DNA methylation, histone modifications can be positive 
or negative regulators of transcription, depending on where they are located within or 
near a gene. For example, H3 methylation within the coding region activates 
transcription, while methylation in the promoter has a negative effect [79]. Each lysine 
has 3 potential methylation sites allowing for mono-, di- and tri-methylated species. 
There are three lysine residues within histones thought to activate transcription- H3K4, 
H3K36 and H3K79. In contrast, H3K9, H3K27 and H4K20 have been implicated in 
repression [78, 80]. However, as mentioned above, H3K9me within the coding region can 
activate gene expression [79]. Lysines can also have an acetyl group added to them 
instead of a methyl group. Histone acetyltransferases (HATs) are less specific than their 
methyltransferase counterparts. One acetyltransferase can act on H3 and H4, and multiple 
lysine residues within each: CBP acetylates K14 and K18 of H3, and K5 and K8 of H4 
[78]. Acetylation activates transcription, while histone deacetylases (HDACs) act to 
repress transcription. Acetylation is also thought to impact chromatin structure. 
Acetylation leads to loss of the positive charge of the lysine side group, which disrupts 
the charge interactions of DNA and the histones. This would lead to an opening of the 
chromatin, making the DNA more accessible for transcription [78]. Similar to the global 
hypomethylation in cancer cells, there is a global decrease in H4K20 trimethylation and 
H4K16 acetylation [81]. Muller-Tidow, et al. analyzed H3K9 methylation in primary 
AML samples and found a decrease in methylation in promoters of hundreds of genes. 
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This decrease often corresponded to an increase in gene expression [82]. Since epigenetic 
alterations are reversible, they are good candidates for treatment. Four epigenetic drugs 
have been approved by the US Food and Drug Administration: two DNMT1 inhibitors 
(5-azacitadine and decitabine) and two HDAC inhibitors (vorinostat and romidepsin) are 
now used clinically, and many more are in development [83]. 
The simplest illustrations of the interplay between genetics and epigenetics in cancer are 
mutations in genes responsible for epigenetic manipulations. There are many cases of 
chromosomal translocations involving HMTs, HDMS, HACs, and HDACs. For example, 
the MLL alterations mentioned above (translocations and MLL-PTD) are present in 5-
10% of adult AML. MLL is the HMT that acts on H3K4 [83-85].  
1.4. Recurrent mutations in AML highlight interactions of genetics and epigenetics 
The impact of mutations affecting DNA methylation is still under investigation. In 
addition to the recurrent mutations discovered in the de novo methyltransferase 
DNMT3A [47, 48, 86] mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) and tet 
oncogene family member 2 (TET2) are also common in AML [87-93]. TET2 is thought 
to function as an indirect DNA de-methyltransferase. It catalyzes the conversion of 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC). The 5-hmC is thought to 
be a target of a specific glycosylase that regenerates the original cytosine residue [94, 95]. 
IDH1/2 then plays an even more removed role in epigenetics. IDH1/2 are involved in 
citrate metabolism; activating mutations result in a neomorphic function of the enzymes 
to generate 2-hydroxyglutarate (2-HG) from alpha-ketoglutarate (αKG). While the novel 
2-HG product may have some toxic effects on the cell, mutant IDH1/2 is thought to affect 
epigenetics by the subsequent decrease in αKG levels, inhibiting proteins (including 
	   15	  
TET2) that are αKG -dependent. Loss-of-function TET2 mutations and gain-of-function 
IDH1/2 mutations would be predicted to have the same outcome, hypermethylation. This 
is supported by the fact that these mutations are mutually exclusive of each other [88]. 
Experimentally, there have been conflicting reports of the consequence of IDH1/2 and 
TET2 mutations. While Ari Melnick’s group found the expected hypermethylation 
phenotype, another group lead by Anjana Rao reported hypomethylation in mutant TET2 
samples [88, 96]. Our own data, which will be discussed in Chapter 2, shows no change 
in global methylation levels with IDH1/2 or TET2 mutations.  
The epigenetic effects of DNMT3A mutations are most likely varied. While the nonsense 
and frame shift mutations must cause loss-of-function, the effect of the missense 
mutations within the methyltransferase domain (including the most common R882 
mutations) is still unknown. There is no difference in total 5-mC content between 
wildtype and DNMT3A mutated AML samples measured by liquid chromatography-
tandem mass spectrometry [47]. While MeDIP-ChIP analysis showed some regions of 
differential methylation in DNMT3A mutant samples, they did not correlate with changes 
in gene expression [47].  
Each of the reprogramming translocations described above also has a link to epigenetics. 
MLL is directly involved in epigenetics, with its role as a histone H3K4 
methyltransferase. AML1-ETO and PML-RARα indirectly affect epigenetic 
modifications through their protein binding partners. AML1-ETO recruits both DNMT1 
and HDAC1 to repressor complexes of AML1 target gene promoters [97]. The 
importance of these associations has been suggested by the use of inhibitors of both 
deacetylases and methyltransferases as anti-leukemic agents [97-99]. PML/RARα also 
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binds multiple epigenetic regulatory proteins, including DNMT3A, JMJD3 (an H3K27 
demethylase), and SETDB1 (an H3K9 methylase) [100, 101]. 
1.5. Acquisition of self-renewal in AML 
One of the main hallmarks of cancer is the acquisition of self-renewal in cancer initiating 
cells. There are 2 main pathways that are currently known to be associated with self-
renewal in hematopoietic stem cells (HSCs) and AML: Notch and HOX. The Notch 
pathway’s role in hematopoiesis is not fully understood, but multiple studies have shown 
its ability to impart self-renewal on hematopoietic progenitors. Notch signaling is 
initiated by binding of ligand (Jagged1 and 2 and Delta1, 3 and 4) to the extracellular 
domain of the Notch receptor. Upon binding, the receptor is cleaved to release the active 
intracellular domain (ICD) into the cell. The Notch ICD then transports to the nucleus 
where it can act on its targets through the transcription factor CSL and the co-activator, 
Mastermind-like (MAML) [102, 103]. Retroviral expression of constitutively active 
Notch ICD in hematopoietic stem cells rendered them immortalized (while still cytokine-
dependent) without losing their ability to generate lymphoid and myeloid progeny [104]. 
While this study suggests that Notch is sufficient for inducing self-renewal in 
hematopoietic progenitors, other studies have shown that it is not required. Conditional 
knockouts of Notch1 and 2—and also Jagged1-- in the hematopoietic compartment did 
not demonstrate a defect in HSC function, nor did blocking Notch signaling downstream 
of the receptor with a dominant negative MAML or conditional knockout of CSL [105-
107]. Taken together, these results suggest that HSCs have redundant pathways for self-
renewal, such as HOX signaling.  
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Notch is involved in a translocation event, t(7;9), where its expression is controlled by the 
TCR locus in rare cases of T cell acute lymphoblastic leukemia (T-ALL) [108]; 
activating mutations of Notch1, however, are present in 50-60% of T-ALL cases [109]. In 
contrast, Notch mutations are very rarely found in cases of AML. Notch is expressed in 
all FAB subtypes, and several AML-associated fusion proteins are capable of activating 
Notch signaling in the absence of ligand [110-113].  
HOX (homeobox containing) genes are a family of transcription factors highly conserved 
from Drosophila to humans. HOX genes were initially identified as regulators of 
positional identity along the anterior-posterior axis of animal models [114]. Their 
expression in hematopoietic progenitors suggests that they may also play a role in 
hematopoiesis, which has been studied extensively with overexpression and knockouts in 
mouse models [115-119]. Overexpression of Hoxb4 in murine HSCs stimulates in vivo 
and ex vivo expansion of HSCs without promoting leukemia, demonstrating its ability to 
promote self-renewal [120-122]. Based on the existence of HOX fusions with 
nucleoporin 98 (NUP98) in rare cases of AML, Keith Humphries’ group has also tested 
multiple NUP98-HOX fusion proteins for their ability to expand HSCs ex vivo [123, 
124]. Like HOXB4 alone, NUP98-HOXB4 is a potent stimulator of HSC expansion, as 
are NUP98 fusions with many other HOX genes (although to varying degrees) [125]. 
Interestingly, when only the homeobox domain of HOXA10 was fused with NUP98 
(NUP98-HOXA10HD) it showed an even greater expansion capacity than NUP98-
HOXB4 (>2000-fold vs. 300-fold) proving that the homeodomain alone is able to induce 
HSC self-renewal [126]. Similar to Notch, knockout models of HOX genes do not lead to 
severe impairments of hematopoiesis, illustrating not only compensation of other self-
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renewal pathways such as Notch, but also the redundancy of the remaining HOX genes 
[127-129]. 
In addition to the NUP98 translocations mentioned above, HOX dysregulation is also 
thought to be a common feature of AML. MLL is an upstream regulator of HOX genes, 
and MLL translocations and MLL-PTD have been shown to cause dysregulation of HOX 
genes [84, 130]. Yan, et al. also reported a significant affect of DNMT3A R882H on 
expression of HOX genes [48]. One report showed that HOXA9 overexpression is the 
most predictive single factor for poor prognosis in AML [131]. On the other hand, NPM1 
mutations are associated with favorable outcome as well as HOX overexpression, 
demonstrating that the role HOX genes play in AML pathogenesis is still poorly 
understood [132-136]. In Chapter 2, we analyze a diverse set of 190 AML patients for 
HOX expression patterns, along with methylation and genetic studies, to better define the 
role of HOX gene dysregulation in AML. 
1.6. Induced Pluripotent Stem cells: in vitro Reprogramming 
1.6.1. The early years: Somatic cell nuclear transfer 
While in vitro reprogramming has become a mainstream technique in the past four years, 
the concept has a much longer history. In the 1990’s, somatic cell nuclear transfer 
(SCNT) was developed as a cloning technique. In this process, the nucleus of a somatic 
cell is removed and inserted into an oocyte, which has had its own nucleus removed. The 
oocyte is stimulated to divide and if successful, will form a blastocyst. While the most 
famous case of SCNT is the cloning of a sheep (Dolly) in 1996, the goal of SCNT was 
not reproductive cloning (which brings with it considerable ethical concerns) but 
therapeutic cloning to produce new embryonic stem (ES) cell lines [137]. SCNT proved 
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to have too many limitations to be practical. First and foremost, the technique requires 
significant manual, tedious work that cannot be moved to a large-scale system. The 
procedure also puts considerable stress on the oocyte and nucleus, so that only a very 
small proportion of transferred cells make it through to the blastocyst stage (from which 
an ES cell line can be made). The reagents themselves are limiting as well, since healthy 
female donors have to provide the oocytes. No ES cell lines have yet been successfully 
generated from SCNT. Since the introduction of transcription factor induced 
reprogramming, the SCNT field has largely been abandoned.  However, very recently a 
group lead by Dieter Egli showed that some of the problems with SCNT can be overcome 
by leaving the oocyte nucleus intact, thereby creating triploid pluripotent cells [138]. 
Whether this finding will lead to a renewal of the SCNT field remains to be seen. Many 
of the limitations of SCNT have been addressed in transcription factor-mediated 
reprogramming. The only technical skills needed are basic tissue culture and viral 
transduction, which can easily be automated.  However, the usefulness of iPS clones for 
generating safe cells for therapeutic purposes has not yet been established. 
1.6.2. Reprogramming goes mainstream 
Since their introduction over four years ago [4], iPS cells have allowed researchers a new 
way to model many biological processes and disease states [139-142]. Much of the 
“hype” surrounding iPS cells, however, is their potential as a therapeutic reagent [143-
145]. This has been the driving force behind many of the modifications to iPS generation 
protocols. The initial 4-retrovirus method had large safety concerns due to retroviral-
induced insertional mutagenesis, as well as the use of c-myc as a reprogramming 
factor,since it is a known oncogene. Reprogramming can now be accomplished without 
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c-myc [146, 147], with single lentiviruses [148-150], and by transiently expressing the 
reprogramming factors as DNA [151, 152], RNA [153] or protein [154].  While there is 
still considerable work being done to maximize efficiency and safety of reprogramming 
protocols, it is clear that we now need to decipher the mechanisms behind reprogramming 
and fully define the iPS phenotype. 
1.6.3. Mechanisms of reprogramming 
In 2009, Shinya Yamanaka published an editorial proposing 2 models to explain the low 
efficiency of iPS reprogramming: the “elite” vs. stochastic models [155]. According to 
the elite model, reprogramming has low efficiency because only a few cells within the 
donor pool are competent for reprogramming.  For example, less-differentiated cells 
within a heterogeneous population are more readily transformed than their fully 
differentiated counterparts. The similarity of the frequency of multipotent stem cells 
within in the skin (0.067%) and initial reprogramming efficiency (~0.05%) support this 
model [156, 157]. However, with improved techniques, along with addition of small 
molecules to enhance reprogramming (such as valproic acid), efficiency is now 
reproducibly seen up to 10%, much higher than stem cell frequency [157, 158]. 
Yamanaka also postulates that since reprogramming efficiency is higher with insertional 
vectors, the positions of retroviral or lentiviral integrations may be important for 
activating or inactivating endogenous genes [155].  
In contrast, the stochastic model states that the majority of differentiated cells are capable 
of reprogramming with alteration of their epigenetic landscape. In 1957 Conrad 
Waddington proposed a model of cell differentiation as a ball rolling down a series of 
slopes from a totipotent stem cell down to a lineage-committed cell. Along the way there 
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are valleys, which keep a cell from traveling in the reverse direction [159]. To maintain 
stem cells, there is an epigenetic block that keeps them from traveling down the path to 
differentiation. In the stochastic model, forced expression of the reprogramming 
transcription factor cocktail can move any cell back up to the totipotent level, but 
epigenetic changes must occur for full reprogramming to occur [155]. 
This “roadblock” hypothesis suggests that reprogramming is a purely epigenetic 
phenomenon, and is currently the dogma in the field. Successful reprogramming requires 
not only loss of methylation from pluripotency-related genes (such as Nanog and Oct4), 
but also new methylation to turn off expression of differentiation genes. Multiple groups 
have shown that iPS cells retain some “memory” of their parental cells at the epigenetic 
level [160]. A recent high-resolution analysis of the methylome of human iPSCs showed 
that although they are globally similar to ES cells, iPSCs have unique methylation 
patterns that could affect their therapeutic potential [161]. A report of successful 
reprogramming of mouse embryonic fibroblasts (MEFs) deficient for Dnmt3A and 
Dnmt3B (the de novo methyltransferases responsible for methylation in ES cells) shows 
that epigenetic changes produced by these genes are not required for reprogramming 
[162]. 
Until recently, karyotyping was the only measure of genomic stability performed on iPS 
cells [5, 6, 163, 164]. This low-resolution view of the genome could easily miss 
deleterious mutations (point mutations, small insertions and deletions, etc.). Earlier this 
year, high-resolution SNP genotyping was performed on human ES cells and iPSCs 
[165]. This study showed that human iPSCs have copy number alterations in oncogenes 
and tumor-suppressor genes not seen in ES cells. Another group used the same approach 
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to compare early- and late- passage human iPS lines. They found that late-passage iPS 
cells have fewer CNVs than early-passage lines, due to selection against highly mutated 
cells with passage in culture [166]. To test how reprogramming affects the genome at the 
nucleotide level, Gore, et al. performed exome sequencing on 22 human iPS lines. These 
lines were produced in multiple labs using five different transcription factor delivery 
protocols, including non-integrating DNA in episomes and messenger RNA. They found 
that each line had on average 5 single nucleotide variants (SNVs) in coding sequences. 
Although not discussed by the authors, there were no significant differences in SNV 
numbers that corresponded to the factor delivery method. They did report that the SNVs 
were enriched for in genes that have been shown to be involved in cancer [167]. They 
also found 3 examples where iPS lines derived in the same experiment from the same 
donor cells harbored identical mutations, but they did not explore this finding, or 
comment on its potential relevance for the “elite” model proposed above. Chapter 3 
details our whole genome sequencing results of ten mouse iPS lines, and introduces the 
idea of an elite model where reprogramming fitness mutations, as opposed to level of 
donor cell differentiation, can sometimes predetermine a cell’s ability to be 
reprogrammed. 
1.7. Summary 
It is clear that we are just beginning to unravel the integration of genetics and epigenetics 
in iPS cells and cancer. With technological advancements in both fields, we now have the 
ability to detect subtle changes --such as single nucleotide mutations and methylation 
changes-- at individual CpG residues. As discussed above, these small alterations can 
have a big impact on cellular function. While translocations have identified groups of 
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favorable and poor risk patients with AML, the intermediate risk category is still 
relatively undefined. The discovery of DNMT3A mutations in 22% of these patients, and 
its impact on outcomes, illustrates the importance of high-resolution genomic studies in 
cancer [47-49]. Technical advancements are also changing the study of epigenetics; 
Illumina’s first generation methylation bead chip covered 27,578 CpG sites across the 
genome. The sites were are all within the proximal promoters of over 14,000 genes 
including genes involved in cancer, imprinting and micro RNAs. The array is highly 
biased, so it could miss many important changes. Recently, Illumina released a new 
methylation bead chip that now covers 450,000 CpG sites. This new array covers 5’ and 
3’ regions of genes with no bias for CpG islands, as was seen in its predecessor (Illumina, 
Inc . San Diego, CA). As shown in Chapter 2 with our analysis of HOX expression in 
AML, by integrating high-resolution epigenetic and genetic techniques, we may be able 
to better understand the process of cellular reprogramming for both iPS cell generation, 
and for cancer pathogenesis. 
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Abstract 
HOX gene dysregulation occurs in acute myeloid leukemia (AML) samples with 
translocations involving HOX genes themselves (e.g. NUP98-HOXA9), and in samples 
with other disease-initiating translocations (e.g. MLL translocations and inv(16)).  
However, HOX genes are also highly expressed in many AML samples without 
translocations; the mechanism that causes “dysregulation” in these cases is unknown. We 
first analyzed the data from 50 sequenced de novo AML genomes and found no recurrent 
mutations within or near the HOX genes that were likely to cause HOX gene 
dysregulation.  Expression array data from 190 AML cases revealed that all AML cases 
with MLL translocations express HOXA cluster genes only, that inv(16) cases express 
HOXB genes only, and that t(15;17) and t(8;21) cases express none of the HOX genes. 
However, most AML cases predominantly express HOXA5, A9, A10, B2, B3, and MEIS1 
in a canonical, highly coordinated fashion that is similar to that found in normal human 
CD34 cells (which contain the hematopoietic stem cell population).  This pattern is 
strongly associated with NPM1 and DNMT3A mutations, but it can be found in AML 
samples with neither mutation. HOX gene expression patterns are not correlated with 
DNA methylation patterns in the HOX gene clusters. HOX gene “dysregulation” in many 
cases of AML may therefore represent the persistence of a normal, stem cell-specific 
HOX gene expression pattern that is probably required for self-renewal, “captured” by 
mutations that initiate disease in the hematopoietic stem cell that was transformed. 
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Introduction 
While there are well known chromosomal translocations associated with favorable 
outcomes (inv(16), t(18;21) and t(15;17)) and poor outcomes (11q23, t(6;9) and 7(q)) [1-
6], most patients have no translocations, and fall into the intermediate risk category. 
Outcomes within the intermediate risk category are highly variable. Many recent studies 
have focused on improving the classification of this large subset of patients, since it could 
improve early treatment decisions; one of the genomic strategies used has been gene 
expression profiling with array-based approaches, in an attempt to find gene expression 
signatures that segregate patients by outcome [6-8]. A recurrent theme seen in these gene-
expression studies is homeobox (HOX) gene dysregulation in many AML patients [6, 9-
13].  
 
HOX genes are a highly conserved family of transcription factors originally identified for 
their role in anterior-posterior axis positioning in animal models [14]. Their expression in 
hematopoietic progenitors suggested that they may also play a role in hematopoiesis, 
which has been studied extensively with overexpression and knockout models in the 
mouse [15-19]. Overexpression of Hoxb4 in murine hematopoietic stem cells (HSCs) 
stimulates in vivo and ex vivo expansion of HSCs without promoting leukemia, 
demonstrating its ability to promote self-renewal [20-22]. Copeland and colleagues 
showed that HoxA7 and A9 are able to cooperate with the Hox co-factor Meis1 to 
generate myeloid leukemia in mice [23]. Further, Nakamura and colleagues showed that 
the HOX genes are down-regulated during myeloid differentiation, implying that their 
role in leukemogenesis may be to block differentiation [24]. 
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The leukemogenic potential of HOX genes is most clearly seen in rare translocations of 
nucleoporin 98 (NUP98) and HOX genes (such as HOXA9, A10, C10 and D13) [25-28]. 
NUP98-HOX fusions replace the regulatory region of the HOX gene with the N-terminus 
of NUP98. Humphries et. al. have tested multiple NUP98-HOX fusion proteins for their 
ability to expand HSCs ex vivo [29, 30]. Like HoxB4 alone, NUP98-HoxB4 is a potent 
stimulator of HSC expansion, as are NUP98 fusions with many other HOX genes 
(although to varying degrees) [31].  A fusion of the homeobox domain alone with NUP98 
(NUP98-HOXA10HD) showed an even greater ability to expand HSPCs than NUP98-
HOXB4 (>2000-fold vs. 300-fold), suggesting that the homeodomain alone is able to 
induce self-renewal [32]. 
 
MLL translocations are also associated with a HOX expression phenotype. Although 
MLL has over 60 fusion partners, HOX genes are never directly involved in MLL 
translocations. MLL is a histone methyltransferase responsible for methylation of H3K4, 
and is regulates HOX gene expression during development [31, 33]. The dependence of 
MLL and HOX genes in hematopoiesis was illustrated by experiments showing impaired 
hematopoietic differentiation by Mll deficient embryoid bodies, which could be rescued 
with overexpression of HOX genes [34]. The HOX overexpression phenotype seen in 
MLL translocations is most likely an effect of altered MLL function in these novel 
fusions [9, 35].  
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Mutations in nucleophosmin (NPM1) are very common in AML, and are also associated 
with high levels of HOX gene expression, even though NPM1 is neither a transcription 
factor nor an epigenetic regulator.  Knockin mice expressing a mutant human NPM1 gene 
(NPM1c) exhibited overexpression of mouse HOX genes in hematopoietic cells, showing 
that the NPM1 mutation can somehow lead to dysregulated HOX expression [36]. More 
recently, mutations in the de novo DNA methyltransferase DNMT3A were shown to be 
highly recurrent in AML [37, 38]. Yan, et al. reported that these mutations are associated 
with hypomethylation and overexpression of HOXB2 and HOXB3 [38].  While mutations 
in both genes have been reported to affect HOX gene expression patterns, the NPM1 
mutation is associated with favorable outcomes, while DNMT3A mutations are associated 
with poor prognosis [37-41].  These studies suggest that HOX overexpression is not 
governed by a simple mutational pattern, and it does predict outcomes per se. 
 
In this study, we analyzed a cohort of 190 carefully genotyped patients to better 
understand/define the HOX expression phenotype in AML. We found that the majority of 
patients express a subset of HOX genes (HOXA5, A9, A10, B2, B3, and MEIS1) at high 
levels. Cases with t(8;21) and t(15;17) minimally express HOX genes; patients with MLL 
translocations only express HOXA family members, and inv(16) cases express only 
HOXB family members . HOX gene expression levels do not correlate directly with 
DNA methylation patterns in the HOX gene clusters, nor are they supervised by any of 
the common recurrent AML mutations.  Surprisingly, we found that the canonical HOX 
expression pattern seen in most AML cases is essentially identical to that of human CD34 
cells; this data suggests that the HOX expression pattern in most cases of AML without 
	   40	  
translocations is not actually dysregulated.  Instead, HOX expression may represent the 
‘capture’ of a normal pattern of HOX gene regulation in HSCs that is responsible for self-
renewal, and subverted by mutations that initiate AML within this cellular compartment. 
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Materials and Methods 
Human AML and normal sorted bone marrow samples 
190 de novo adult AML bone marrow aspirates were analyzed. Patient selection has been 
previously described [42]; patient characteristics are listed (including recurrent 
mutations) in Table 2-1. Bone marrow aspirates were also obtained from healthy adult 
donors. This study was approved by the Human Research Protection Office at 
Washington University School of Medicine after patients and donors provided informed 
consent in accordance with the Declaration of Helsinki. Isolation of normal 
promyelocytes and neutrophils were performed as previously described [43]. Briefly, 
CD9-, CD14-, CD15hi, and CD16lo promeylocytes and CD9-, CD14-, CD15hi, and 
CD16hi neutrophils were isolated by high-speed cell sorting. CD34+ cells were isolated 
by MACS sorting according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch 
Gladbach, Germany).  
 
DNA and RNA Isolation and Purification 
DNA was extracted from AML bone marrow aspirates using the QIAamp DNA Mini Kit 
according to the manufacturer’s instructions (Qiagen, Valencia, CA).  DNA from all 
samples was quantified using UV spectroscopy (Nanodrop Technologies, Wilmington, 
DE). RNA from AML bone marrow aspirates was prepared from unfractionated snap-
frozen cell pellets using Trizol reagent. For the sorted healthy bone marrow samples, 
sufficient cells were collected to perform the standard 1-cycle in vitro transcription 
protocol; avoiding the bias introduced by linear amplification (2-cycle) required for 
smaller amounts of RNA. Sorted cells were lysed in Trizol reagent (Invitrogen, Carlsbad, 
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CA) and stored at -80oC until RNA purification. RNA from all samples was quantified 
using UV spectroscopy (Nanodrop Technologies, Wilmington, DE) and qualitatively 
assessed using a BioAnalyzer 2100 and RNA NanoChip assay (Agilent Technologies, 
Santa Clara, CA).  
 
Analysis of RNA from AML and healthy cell populations 
Gene chip analysis of all samples was done as previously described [44]. Samples were 
labeled and hybridized to Affymetrix Human Genome U133 Plus 2 Array GeneChip 
Microarrays (Affymetrix, Santa Clara, CA) using standard protocols. For 70 of the 190 
patients, the Affymetrix data was orthogonally validated on the NanoString nCounter 
platform (see Table 2-1 for patient identifiers). Details of the nCounter Analysis System 
(NanoString Technologies) were reported previously [45]. Briefly, two sequence-specific 
probes were generated for each gene of interest (Table 2-4). The probes were 
complementary to a 100-base region of the target mRNA. One probe was covalently 
linked to an oligonucleotide containing biotin (the capture probe), and the other was 
linked to a color-coded molecular tag (the reporter probe). The nCounter CodeSet for 
these studies contained probe pairs for 46 test and control genes (data not shown for 
control genes). Each sample was hybridized in duplicate with 100 ng of total RNA in 
each reaction. All 46 genes were assayed simultaneously in multiplexed reactions. To 
account for slight differences in hybridization and purification efficiency, the raw data 
were normalized to OAZ1 (one of the control genes). Spearman correlations were 
calculated using SAS 9.1 statistical software to determine the correlation of NanoString 
and Affymetrix data, values are reported in Table 2-4. 
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Analysis of Affymetrix U133 Plus 2 array data 
Spotfire software was used to generate heatmaps from the raw expression values for the 
best probe set of each HOX gene (defined as the probe set with the highest average 
expression level across all 190 samples- listed in Table 2-4). Samples were organized by 
translocations, mutations, and HOX expression levels as indicated. For heatmaps, 
maximum expression was set to a raw expression value 10,000 (red) and minimum was 
set to 0 (green), with a midpoint of 5000 (black). To correlate expression of genes with 
HOXA9, in an attempt to identify a potential upstream regulator, expression levels of all 
54,613 probesets were compared to HOXA9 expression in all 190 samples.  
 
Measuring 5-methylcytosine content by mass spectrometry. 
Analysis was done as previously described [37]. Briefly, Samples were analyzed by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a Shimadzu SCL-
10A VP HPLC system (Columbia, MD) coupled with a 4000 Q-Trap (MS/MS) mass 
spectrometer (Applied Biosystems, Foster City, CA). The Analyst software package 
(Version 1.4.2, Applied Biosystems, Foster City, CA) was used for instrument operation, 
data acquisition and analysis.  Standard curves were generated using commercially 
available deoxyribonucleoside compounds (5-methyl-2’-deoxycytidine monophosphate 
disodium salt (mdCMP), 2’-deoxyguanosine-5’-monophosphate disodium salt (dGMP), 
2’-deoxyadenosine-5’-monophosphate free acid (dAMP), 2’-deoxycytidine 
monophosphate sodium salt (dCMP), thymidine (T), 2’-deoxyadenosine monohydrate 
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(dA), 2’-deoxycyidine (dC) (USB Corporation, Cleveland, OH and Sigma Aldrich, St. 
Louis, MO). The LC-MS-MS analysis for patient samples was performed using 3.5-5 
ng/µL of DNA hydrolysis products. The percentage of methylation was determined by 
either dividing the measured amount of mdCMP (in fmols) by the amount of dGMP in 
each sample or by dividing the sum of mdCMP and dCMP detected in each sample. 
 
Bisulfite conversion of genomic DNA for methylation analysis  
Cytosine residues in DNA samples (1 µg) were converted to thymidine with bisulfite 
using the Zymo Research EZ96 DNA methylation kit, according to the manufacturer’s 
instructions (Zymo Research, Irvine, CA, USA). The completeness of bisulfite 
conversion and the amount of bisulfite-converted DNA for each sample was determined 
using a panel of four MethyLight-based quality control (QC) reactions as described 
previously [46]. All samples passed these QC tests and subsequently were entered into 
the Illumina Infinium DNA methylation data production pipeline. 
 
Infinium DNA methylation profiling 
The Illumina Infinium HumanMethylation450 DNA methylation assay was performed 
for all 190 samples according to the experimental protocol outlined by the manufacturer 
(Illumina, San Diego, CA, USA; User Guide part #15019519 A). The Illumina Infinium 
DNA methylation assay interrogates the DNA methylation status of 485,577 CpG 
dinucleotides as described [47]. The genomic characteristics of each probe are available 
for download via Illumina (ftp.illumina.com); our annotations are based upon version 1.2 
of the HumanMethylation450 manifest. BeadChips were coated and imaged on an 
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Illumina iScan station.  Binary IDAT files produced by the scanner were then processed 
directly using a development version of the Bioconductor methylumi package (Triche, 
2011). 
 
Data extraction and analysis.  Analytic and control probe average intensities, as well as 
the number of beads registered for each probe, were extracted directly from IDAT files 
produced by the scanner. Background correction was performed via normal-exponential 
convolution on out-of-band intensities from 135,501 of the 485,577 analytic probes, 
taken to estimate within-array background [48].  An offset of +15 was employed as 
recommended by Shi, et al. [48]. Following background correction, beta values for each 
probe were computed as the fraction of the total intensity contributed by the methylated 
probe allele (M/(M+U)) for each of the 485,577 probes on the array.  Non-detection 
probabilities (p-values) were computed using the empirical cumulative density function 
of the negative control probes in the appropriate channel for each allele [48]. Probes 
with fewer than three registered beads, or greater than a 0.01 (> 1%) non-detection 
probability for both alleles, were flagged as N/A and omitted from further analysis. 
Probes interrogating a CpG locus within 10 base pairs of a known single nucleotide 
polymorphism (SNP) were also omitted from analysis.   
 
Data submission.  Raw IDAT files and processed data for 190 patients with matching 
DNA methylation and gene expression data were deposited with the Data Coordination 
Center for the Cancer Genome Atlas project and are available from the TCGA Data 
Portal: http://tcgadata.nci.nih.gov/tcga/dataAccessMatrix.htm?mode=ApplyFilter&show 
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Matrix=true&diseaseType=LAML&availability=A&tumorNormal=TN&tumorNormal=
T&platformType=2. 
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Results  
 
Somatic mutations within the HOX gene clusters do not account for HOX gene 
overexpression in AML 
To determine if HOX overexpression in AML is due to somatic mutations within or near 
the HOX genes, we analyzed the HOX gene cluster region from the whole genome 
sequencing results of 45 de novo AML samples with either normal karyotypes (n=35), 
MLL translocations (n=2) or t(15;17) (n=8). These patients represented a range of FAB 
subtypes, patient ages, and survivals (full patient details are in Table 1) as well as a wide 
range of HOX gene expression levels on the AffyMetrix U133+2 array (Figure 1). We 
defined somatic mutations in each of the four HOX gene clusters by comparing the 
sequence data from the bone marrow DNA to normal skin DNA, in a region that spanned 
from 100 kb upstream from the 5’- most gene to 100 kb downstream from the 3’- most 
gene. Ten of 45 samples contained somatic mutations within the HOX clusters (Table 2). 
The 10 patients with mutations are indicated in Figure 1, which shows that the mutations 
are not associated with the HOX gene expression phenotype.  One sample had two 
mutations within 70 kb of each other in the HOXC cluster; both were in non-coding 
regions. The mutation closest to a gene was found 1,586 bp upstream from HOXA13. 
Although it is possible that some of these mutations could affect previously undefined 
regulatory regions, none were recurrent, and none were directly associated with patterns 
of HOX gene expression. None of the mutations were found within coding regions, and 
therefore none had translational consequences.  
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A canonical pattern of HOX gene expression in AML 
As opposed to mouse models of AML, and NUP98-HOX fusion cases of human AML 
where single HOX genes are overexpressed, the data shown in Figure 1 suggests that 
there is a specific set of HOXA and HOXB cluster genes that are highly expressed in 
some AML cases (predominantly HOXA5, A9, A10, B2, B3, and MEIS1). Notably, HOX 
C and D cluster genes are rarely expressed in AML samples.  To determine whether these 
patterns were restricted to normal karyotype cases, we increased our analysis to a total of 
190 AML patients with a wide variety of cytogenetic and clinical features (Table 1). 
Figure 2 and Table 3 reveal the same canonical pattern of HOX gene expression in many 
of the samples in this larger set, with notable exceptions described below.   
 
Due to the homology of homeobox domains in HOX genes, probe cross-hybridization 
could potentially explain the highly correlated expression patterns. 
The HOX genes are most highly related among the paralog groups (i.e. HOXA9, HOXB9, 
HOXC9 and HOXD9) and Figure 1 shows that the Affymetrix probes can clearly 
distinguish among the expression levels of these genes.  Regardless, we measured the 
expression levels of all HOX genes (and MEIS1) on an orthogonal platform (the 
NanoString nCounter platform) for 70 of the 190 AML samples; these values were highly 
correlated between the platforms for all HOX genes (Table 4).  These data suggest that 
the Affymetrix U133 Plus 2 platform accurately measures patterns of HOX gene 
expression. 
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Unique patterns of HOX gene expression associated with AML translocations 
Since AML-associated translocations have been linked with HOX gene overexpression, 
we compared patterns of HOX gene expression to cytogenetic and mutational data from 
the 190 AML cases. Figure 4A contains a heatmap that shows that samples with several 
well-defined AML translocations have unique HOX gene expression patterns; the actual 
expression values for each gene and patient are plotted in Figure 4B.  Remarkably, none 
of the cases with t(15;17) or t(8;21) express any of the HOX genes. In contrast, cases 
with inv(16) express relatively low levels of only HOXB2, HOXB3, and MEIS1. As 
previously reported, MLL translocation cases uniformly overexpress HOXA5, HOXA9, 
and HOXA10, along with MEIS1; HOX B genes are not expressed in these cases, 
however. Patients with the MLL-PTD mutation express both HOXA and HOXB cluster 
genes in the canonical pattern seen with normal karyotype cases, suggesting that these 
two mutation types may have different operational mechanisms.  
 
A variety of mutations associated with AML have also been reported to have 
dysregulated HOX gene expression. We therefore correlated HOX gene expression 
patterns with several common AML mutations in Figure 5. As previously reported, all 
AML cases with the NPM1 mutation exhibit the canonical HOX expression phenotype 
[39, 41, 49]. DNMT3A mutations, on the other hand, do not fully correlate with the 
phenotype; only 11/25 (44%) of patients with DNMT3A mutations alone have the 
canonical HOX expression pattern (for this analysis, the canonical HOX expression 
pattern was defined as raw values for HOXA9 and HOXB3 greater than 5,000 on the 
Affymetrix U133 Plus 2 array platform). DNMT3A mutations are positively correlated 
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with NPM1 mutations [37]; if the doubly mutant cases are taken into account, the 
canonical HOX phenotype is detected in 33 of 47 cases (70%). FLT3, IDH1/2 and TET2 
mutations all exhibit ~65% of cases with the canonical HOX phenotype (including 
patients with mutations in NPM1 and/or DNMT3A mutations). While this data reveals 
positive correlations of the canonical HOX phenotype with some mutations, it also shows 
that some cases have the phenotype despite having none of the correlated mutations.  
 
DNA methylation patterns near the HOX genes do not correlate with expression 
DNMT3A, IDH1/2 and TET2 mutations have all been suggested to have effects on DNA 
methylation [38, 50, 51]; since there have been conflicting reports on the affect of these 
mutations on global DNA methylation, we first measured total 5-methylcytosine content 
by mass spectrometry in 70 selected samples [37]. Our data shows no significant 
association of 5-methylcytosine levels with any of the methylation-associated mutations 
(Figure 6). To determine whether the methylation status of the HOX gene clusters is 
associated with HOX expression levels, as suggested by Yan, et al., we examined data 
from the Infinium Human Methylation 450 BeadChip (Illumina, San Diego, CA) for the 
same 190 patients for which expression data was available. Figure 7 shows methylation 
data across the entire HOXA gene cluster (there are 542 CpG probes on the array that fall 
within this locus). The map was organized by the expression level of HOXA9, with 
lowest levels at the top, and highest at the bottom; there is no corresponding methylation 
gradient at the HOXA9 promoter, or anywhere else in the HOXA gene cluster. The 
methylation array contained 450 CpG probes within the HOXB gene cluster; a minor 
hypomethylation phenotype was detected upstream from the HOXB3 gene in some 
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samples with high levels of HOXB3 expression (Figure 8; hypomethylation was defined 
as an average beta-value of less than 40% across the region of interest. This 
hypomethylation pattern is seen in 56% (36/64) of the top third of samples ranked on 
HOXB3 expression. However, the hypomethylated samples do not cluster apart from the 
methylated samples, suggesting that hypomethylation is not the direct cause of HOXB3 
gene overexpression. By organizing the methylation data based on the common AML 
somatic mutations, there is no evidence of a phenotype in any of the 4 HOX gene clusters 
that is supervised by any of the common AML mutations (Figure 9). 
  
The canonical HOX expression phenotype is also detected in normal human CD34 
cells 
Since neither mutations nor methylation patterns explain the canonical HOX phenotype, 
we next analyzed HOX gene expression patterns in normal hematopoietic cells. We 
analyzed expression array data from CD34+ cells, promyelocytes, and neutrophils 
purified from the bone marrow cells of five healthy volunteers [44].  Normal human 
CD34 cells express the same HOX genes as AML cells with the canonical phenotype 
(Figure 10); HOXA and B gene expression was downregulated in promyelocytes and 
neutrophils.  To compare relative levels of expression in CD34 cells and AML samples, 
we normalized the expression of each gene to 100% for HOXA9 (which is always the 
maximally expressed gene) in all samples (Figure 11). Remarkably, the relative 
expression of all HOX genes with respect to HOXA9 is essentially the same in CD34 
cells and AML cells. 
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Potential mechanisms underlying the canonical HOX expression phenotype 
Since the HOXA and HOXB gene clusters are on different chromosomes, their 
coexpression in AML samples suggests that one or more trans-acting factors coregulate 
their expression. To identify potential trans-acting regulators in silico, we searched for 
common transcription factor motifs unique to the promoter regions of the expressed HOX 
genes. No common motifs were identified within 2,000 bp of HOXA5, HOXA9, HOXA10, 
HOXB2, HOXB3 and MEIS1 that were absent from the other HOX gene promoters (data 
not shown).  We then analyzed all probesets on the AffyMetrix U133+2 array to identify 
genes with expression levels that were significantly correlated HOXA9, using a 
Spearman’s correlation test.  Of the 54,000+ probesets on the array, the only genes that 
were significantly coregulated were HOXA9, HOXA5, HOXA10, HOXB2, HOXB3 and 
MEIS1 (data not shown).  
 
To determine whether clues regarding HOX gene regulation could be gleaned from 
mouse hematopoietic cells (which are easier to experimentally manipulate), we generated 
expression array data using the Affymetrix mouse Exon 1.0 array platform. We purified 
SLAM cells, KLS cells, promyelocytes, and neutrophils from at least three different 
young C57Bl/6 mice, and examined the HOX gene expression patterns from the arrays 
(Figure 12).  Although the Meis1 gene is developmentally regulated in a pattern that 
mimics human hematopoietic development, the Hoxa and Hoxb genes are not 
downregulated during terminal myeloid differentiation, and the pattern of expression is 
very different from that of human CD34 or AML cells.  Unlike patients with AML FAB 
M3 and the t(15;17) translocation (which express none of the HOX genes), our mCG-
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PML-RARA mouse model of APL expresses Hox genes in a pattern that is similar to that 
of normal progenitors (Figure 13).  
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Discussion 
In this study, we explored HOX gene expression levels in a diverse group of AML 
patients, and found that four patterns exist based on cytogenetic findings: 1) 
Translocations that have no detectable effects on HOX gene expression (i.e. t(8;21) and 
t(15;17))  2) Translocations associated with exclusive expression of either HOXA genes 
(MLL translocations) or HOXB genes (inv(16)); 3) Normal karyotype with a canonical 
pattern of expression of HOXA5, A9, A10, B2, B3, and the HOX co-factor MEIS1; 4) 
Normal karyotype with HOX gene expression below the level of detection.  None of the 
common AML mutations supervise the canonical pattern of HOX gene expression, and 
DNA methylation patterns are not consistently correlated with HOX gene expression 
patterns. While many groups have reported HOX gene “dysregulation” in AML [9, 11, 
12, 17, 23, 39, 40, 52-56], our studies clearly show that AML cases with the canonical 
pattern of HOX gene expression have the same pattern as that of normal human CD34 
cells.  These findings suggest that “dysregulation” in these AML cases more likely 
represents the “capture” of a normal pattern of HOX gene expression that is associated 
with the self-renewal properties of HSCs.  The preservation of the HOX gene program in 
these cells may serve a mechanism to preserve self-renewal, an essential property of 
leukemia initiating cells. 
 
Acquisition of self-renewal is thought to be a necessary step for the initiation of 
leukemia. Multiple pathways have been implicated in self-renewal in HSCs, including the 
HOX genes, along with the Notch, Hedgehog, Wnt, and FOXO signaling pathways [57]. 
Leukemia initiating fusion genes created by translocations, such as t(8;21) and t(15;17) 
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have been shown to directly induce self-renewal in mouse models [58, 59]; clearly, these 
translocations cause self-renewal via Hox-independent mechanisms. In support of this 
notion, our group has now shown that PML-RARA may initiate self-renewal program 
through the Notch pathway, since dominant negative MAML can abrogate the serial 
replating phenotype induced by PML-RARA (N. Grieselhuber, et. al. in preparation). We 
further analyzed the gene expression patterns of the four non-HOX self-renewal 
pathways to see if they are differentially expressed in normal karyotype patients with and 
without HOX expression; the majority of genes in these pathways are not expressed in 
AML samples. The genes that are expressed show no difference between the HOX 
positive and negative normal karyotype samples, suggesting that these pathways are not 
responsible for self-renewal in the HOX negative samples.  A complete understanding of 
the genetic and epigenetic pathways in a large number of AML cases will be needed to 
identify all of the self-renewal pathways that are activated in this disease. 
 
As opposed to the highly conserved t(15;17) translocation, MLL mutations represent a 
heterogeneous group of AML-associated mutations with variable HOX expression levels. 
While the MLL-PTD mutation is associated with the canonical expression pattern of 
HOXA and HOXB genes seen in the majority of cases of AML, MLL translocations are 
associated with overexpression of only the HOXA5, A9, and A10 genes. This implies that 
the MLL fusion proteins have a restricted set of HOX target genes, compared to 
constitutively active MLL. Since MLL is a known upstream regulator of HOX genes, the 
link between MLL mutations and HOX gene overexpression is thought to be direct. 
However, most AML samples with HOX gene overexpression have no mutations 
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affecting MLL. Although other genes that have been reported to regulate HOX 
expression (e.g. MOZ, CDX2, and polycomb gene complex members), no mutations have 
been found in these genes in our set of sequenced AML samples (TJ Ley, et al., 
unpublished) and their expression does not correlate with HOX gene overexpression 
patterns in our samples [26, 60-63]. 
 
Finding the canonical HOX expression phenotype in a large subset of patients harboring 
DNMT3A, IDH1/2 and/or TET2 mutations suggested a potential role for DNA 
methylation in controlling HOX gene expression patterns. However, global 
methylcytosine levels are not altered in patients with these mutations, and the 
methylation array data did not reveal a correlation between these mutations and CpG 
methylation in the HOX gene clusters. Our data conflicts with the report from Yan et. al., 
who demonstrated hypomethylation at 5 CpG dinucleotides in the HOXB2 promoter of 17 
DNMT3A mutated samples. In this study, we used the Infinium array to examine 992 
CpG residues in the HOXA and HOXB loci of 47 AML samples with DNMT3A mutations 
and 143 samples without [38]. Although we did detect a small group of samples with 
hypomethylated regions in the HOXB2 promoter, this finding was not restricted to 
DNMT3A mutant cases, and it was not linked directly to HOXB2 overexpression.  
Although it is very unlikely that DNA methylation plays a major role in the regulation of 
HOX gene expression patterns, we cannot rule out a role for histone modifications; 
indeed, two of the known regulators of HOX genes, MLL and MOZ, modify histones and 
may directly affect HOX expression patterns [61].  A careful study of histone 
modifications in the HOX loci of primary AML cells may help to identify the key 
	   57	  
upstream modifiers, if adequate numbers of viable cells can be obtained for CHiP-Seq 
analysis. 
 
The coordinated, canonical expression of HOXA and HOXB genes, which lie on separate 
chromosomes, suggests the presence of an upstream transcriptional regulator. We 
performed an in silico analysis to identify a common transcription factor binding motif 
for the expressed HOX genes, but none was identified.  We searched for AML genes that 
were coregulated with HOXA9 in an attempt to find an upstream transcription factor, but 
found only the expressed HOX genes themselves (A9, A5, A10, B2, B3, and MEIS1). 
These data suggest that an autoregulatory loop may govern the expression of this subset 
of HOX genes.   Although Hox gene autoregulation has previously been demonstrated in 
Drosophila, it has not yet been proven to occur in higher organisms [64]. Unfortunately, 
mice and humans express different subsets of HOX genes in hematopoietic cells, and 
regulate HOX genes differently during hematopoietic development; modeling an 
autoregulatory loop that mimics the human situation may therefore be difficult to achieve 
in murine systems. 
 
 
Although HOX gene overexpression in AML has been appreciated for years, we have 
used genomic data to establish the differences between expression patterns in cases with 
and without common AML translocations; we have also defined a canonical HOX gene 
expression pattern in AML that is also found in normal human CD34 cells. Considering 
how common the “HOX phenotype” is in NK-AML cases, these results suggest that the 
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leukemia-initiating cell may often be a transformed HSC that retains its original HOX 
expression pattern. Since murine hematopoietic cells express different HOX genes in 
different patterns, modeling this phenomenon experimentally will be difficult. Although 
the mechanism underlying the HOX hematopoietic phenotype is still unclear, these data 
clarify the circumstances and patterns of HOX gene expression in many cases of AML.  
These data also show that it may be very difficult to differentially target the HOX 
pathway in AML, since it reflects the normal pattern of HOX gene expression in HSCs, 
where elimination of self-renewal would be expected to have disastrous consequences. 
Much additional work will be needed to identify all the genetic and epigenetic events that 
cause self-renewal in AML, and whether some will represent bona fide targets for novel 
therapeutic approaches. 
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Figure Legends 
Figure 2-1. Heat map of expression data for MEIS1 and the HOX cluster genes from 
45 de novo AML patient samples for which there is whole genome sequencing data.   
RNA expression is plotted according to the normalized array mean, using a linear scale 
from 0 (green) to 5000 (black) to 10,000 or greater (red).  Each row represents a patient 
and each column represents a single probeset from the Affymetrix U133 Plus 2 array. 
Translocations and mutations for each patient are indicated to the right, along with 
availability of RNASeq data. “Other” refers to patients with any cytogenetic abnormality 
that is not otherwise annotated. Patients are arranged according to cytogenetics. Numbers 
1-10 to the right of the heatmap indicate the patients harboring the mutations listed in 
Table 2.  
 
Figure 2-2. Raw data from Affymetrix U133 Plus 2 array for 190 patients de novo 
AML patient samples.  
Each of the overexpressed HOX genes is plotted against each other to determine intra-
HOX correlations. r2 values are indicated, a complete list of r2 and p-values for all of the 
combinations is in Table 3. 
 
Figure 2-3. Correlation of patient characteristics and HOX Expression. 
Expression values of HOXA (left) and HOXB (right) plotted against sex (A), age (B), 
%BM blast (C), EFS (D) and OS (E). p- and r2- values are indicated for each comparison. 
None of the patient characteristics show a significant correlation with HOX expression. 
 
Figure 2-4. A. Heat map of expression data for MEIS1 and the HOX cluster genes 
from 190 de novo AML patient samples by cytogenetics.   
RNA expression is plotted according to the normalized array mean, using a linear scale 
from 0 (green) to 5000 (black) to 10,000 or greater (red).  Each row represents a patient 
and each column represents a single probeset from the Affymetrix U133 Plus 2 array. 
Translocations and mutations for each patient are indicated to the right, along with 
availability of RNASeq data. “Other” refers to patients with any cytogenetic abnormality 
that is not otherwise annotated. Patients are arranged according to cytogenetics. B. Raw 
data from Affymetrix U133 Plus 2 array for 190 patients de novo AML patient samples 
shown in Panel A. Samples are categorized by translocations and mutations. “Other” 
refers to patients with any cytogenetic abnormality that is not otherwise annotated. 
 
Figure 2-5. A. Heat map of expression data for MEIS1 and the HOX cluster genes 
from 190 de novo AML patient samples by recurrent mutations.   
RNA expression is plotted according to the normalized array mean, using a linear scale 
from 0 (green) to 5000 (black) to 10,000 or greater (red).  Each row represents a patient 
and each column represents a single probeset from the Affymetrix U133 Plus 2 array. 
Translocations and mutations for each patient are indicated to the right, along with 
availability of RNASeq data. “Other” refers to patients with any cytogenetic abnormality 
that is not otherwise annotated. Patients are arranged according to mutation status. B. 
Raw data from Affymetrix U133 Plus 2 array for 190 patients de novo AML patient 
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samples shown in Panel A. Samples are categorized by mutations and translocations. 
Patients with DNMT3A mutations are split into DNMT3A R882 mutations and “other” for 
non-R882 mutated residues. 
 
 
Figure 2-6. LC-MS data of total methylcytosine content for 70 de novo AML 
patients.  
Samples are categorized by mutations and translocations. Patients with DNMT3A 
mutations are split into DNMT3A R882 mutations and “other” for non-R882 mutated 
residues. 
 
Figure 2-7. Methylation array data of the HOXA locus from 190 de novo AML 
patient samples by HOXA9 expression. 
Estimated proportion of cytosine methylation in 190 de novo AML patient samples at loci 
within the HOXA cluster of genes, ordered left-to-right in the direction of transcription 
(reverse strand orientation).  Methylation is estimated as the proportion of overall 
fluorescence intensity contributed by the methylated probe allele.  Each row represents 
one patient and each column represents one interrogated cytosine probed by the Illumina 
HumanMethylation450 array. Translocations and mutations for each patient are indicated 
at right, along with availability of RNASeq data. ‘Other’ refers to patients with any 
cytogenetic abnormality that is not otherwise annotated. Patients are arranged bottom-to-
top in descending order of HOXA9 expression. HOXA9 and B3 expression are shown 
shown in the left-most columns with a scale of 0 (white) to 10,000 (red). 
 
Figure 2-8. Methylation array data of the HOXA locus from 190 de novo AML 
patient samples by HOXB3 expression. 
Estimated proportion of cytosine methylation in 190 de novo AML patient samples at loci 
within the HOXB cluster of genes, ordered left-to-right in the direction of transcription 
(reverse strand orientation).  Methylation is estimated as the proportion of overall 
fluorescence intensity contributed by the methylated probe allele.  Each row represents 
one patient and each column represents one interrogated cytosine probed by the Illumina 
HumanMethylation450 array. Translocations and mutations for each patient are indicated 
at right, along with availability of RNASeq data. ‘Other’ refers to patients with any 
cytogenetic abnormality that is not otherwise annotated. Patients are arranged bottom-to-
top in descending order of HOXB3 expression. HOXA9 and B3 expression are shown 
shown in the left-most columns with a scale of 0 (white) to 10,000 (red). 
 
Figure 2-9. Methylation array data of the HOXA and HOXB loci from 190 de novo 
AML patient samples by recurrent mutations. 
Estimated proportion of cytosine methylation in 190 de novo AML patient samples at loci 
within the HOXA (Panel A) and HOXB (Panel B) cluster of genes, ordered by left-to-
right by direction of transcription (reverse strand orientation).  Methylation is estimated 
as the proportion of overall fluorescence intensity contributed by the methylated probe 
allele.  Each row represents one patient and each column represents one interrogated 
cytosine probed by the Illumina HumanMethylation450 array. Translocations and 
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mutations for each patient are indicated at right, along with availability of RNASeq data. 
‘Other’ refers to patients with any cytogenetic abnormality that is not otherwise 
annotated. Patients are arranged according to mutation status; patients without major 
recurrent mutations are then arranged according to cytogenetic status. 
 
Figure 2-10. HOX expression levels in healthy hematopoietic cells.  
A. Heat map of expression data for MEIS1 and the HOX cluster genes from peripheral 
blood of healthy patient samples. Cells were sorted into different lineages- CD34+ cells 
(enriches for HSCs), committed progenitors (promyelocytes) and fully differentiated 
neutrophils (PMNs) (n=5 each). RNA expression is plotted according to the normalized 
array mean, using a linear scale from 0 (green) to 5000 (black) to 10,000 or greater 
(red).  Each row represents a patient and each column represents a single probeset from 
the Affymetrix U133 Plus 2 array. B. Raw data from Affymetrix U133 Plus 2 array for 
healthy patient samples shown in Panel A.  
 
Figure 2-11. Comparison of HOX expression pattern in AML vs. healthy 
hematopoietic cells.  
For each cell type, expression level for each gene was averaged across all samples. For 
the AML samples only the 89 normal karyotype samples were analyzed since the 
translocations have unique expression patterns. Since the CD34+ cells are not purely 
HSCs, the HOX raw expression data is lower than that of the pure AML samples. 
Therefore, the healthy hematopoietic cells were then normalized with CD34+ HOXA9 
expression set to 100% and the AML samples were normalized separately to AML 
HOXA9 expression set to 100%.   
 
Figure 2-12. HOX expression pattern in mouse hematopoietic cells.  
Raw data across all 4 HOX loci and Meis1 from Affymetrix Mouse 430 2.0 array for cell 
populations enriched for HSCs (SLAM and KLS) as well as committed progenitors 
(promyelocytes) and full differentiated neutrophils.  
 
Figure 2-13. HOX expression pattern in mouse acute promyelocytic leukemia 
samples.  
Raw data across all 4 HOX loci and Meis1 from Affymetrix Mouse 430 2.0 array for cell 
populations enriched for HSCs (SLAM and KLS) in acute promyelocytic leukemia 
(APL) mouse models (mCG-PR and CTSG KO) as well as APL tumor. 
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Table 2-1. Clinical characteristics of 190 de novo AML patients 
 
  
UPN
NanoString,
data WGS Age Sex Race FAB Cytogenetics
%BM,
Blast
PB,WBC@,
presentation
%PB,
Blast
Vital,
Status,,
(4.29.11)
EFS,
months,,,,
(4.29.11)
OS,
months,
(4.29.11) MLL,status DNMT3A DNMT3A,mutation,consequences FLT3 FLT3,other, IDH1, IDH2, NPM1,
103342 Yes Yes 61 F W M2 normal 43 9.8 32 Alive 35.6 36.1
113971 Yes Yes 57 F W M2 normal 43 3.5 35 Dead 8.6 28.4
G590fs/@1.5Mb@
deletion
adds@28@aa@before@stop/del,@
chr2:24,460,563H25,807,506@
R140Q
142074 Yes Yes 60 M W M4 normal 89 79.9 56 Dead 9.9 11.3 R882H missense ITD W288fs
224143 Yes Yes 67 F W M1 normal 76 45.6 49 Dead 0.8 0.8 F909C missense W288fs
225373 Yes Yes 71 F W M2 normal 70 35.9 67 Dead 0.8 0.8 R132C
246634 Yes Yes 79 M W M4 normal 58 18.5 0 Dead 14.6 14.6 A741V,E477* missense/nonsense
273919 Yes Yes 25 M W M2 normal 56 126.1 71 Alive 51.5 51.5
335640 Yes Yes 67 F W M5 normal 85 93.3 3 Dead 2.5 2.5 R882C missense D835Y W288fs
426980 Yes Yes 68 M W M2 normal 64 5.5 48 Dead 26.2 46.8 R140L
445045 Yes Yes 75 M W M2 normal 63 2.5 2 Alive 62.1 62.1
452198 Yes Yes 55 M W M5 normal 97 72.6 8 Alive 16.6 53.8 R882H missense D835H R132H W288fs
456892 Yes Yes 58 M W M4 normal 58 19.9 10 Alive 45.0 45.0 E505* nonsense W288fs
509754 Yes Yes 21 F W M1 normal 91 8.2 83 Alive 73.9 73.9 R132S W288fs
545259 Yes Yes 30 F W M1 normal 86 22.9 88 Alive 33.7 33.7
548327 Yes Yes 51 M W M1 normal 85 63.7 85 Alive 31.9 31.9 R132G W288fs
573988 Yes Yes 67 F W M4 normal 75 15.2 10 Dead 12.0 20.5 R140Q W288fs
700717 Yes Yes 45 M W M0 normal 75 2.3 0 Dead 3.8 11.2 MLL.PTD@exon3Hexon11
775109 Yes Yes 45 M W M5 normal 81 1.6 0 Alive 81.4 81.4 MLL/AF10@(RNA)
807970 Yes Yes 38 M W M1 normal 86 39.8 97 Alive 54.9 54.9 R132C W288fs
808642 Yes Yes 61 M W M1 normal 49 2.9 14 Dead 12.0 15.5 ITD
816067 Yes Yes 35 F W M5 normal 87 156.1 8 Alive 33.9 33.9 R882C missense ITD R132C W288fs
817156 Yes Yes 54 M B M2 normal 67 45.0 83 Dead 8.5 34.0 MLL.PTD@exon3Hexon11 R882H missense
831711 Yes Yes 57 F W M1 normal 64 2.5 61 Alive 53.4 53.4
MLL.PTD@intron2H
exon9,@exon3Hexon9
869586 Yes Yes 23 M W M4 normal 51 27.1 63 Dead 7.7 19.0
906708 Yes Yes 76 F W M4 normal 91 5.0 16 Dead 17.0 25.8 W288fs
933124 Yes Yes 57 F W M1 normal 100 105.2 91 Dead 11.1 24.6 L723fs adds@56@aa@before@stop ITD W288fs
991612 Yes Yes 63 M W M2 normal 35 0.6 0 Alive 62.0 62.0
123172 No Yes 56 M W M1 normal 90 30.5 45 Dead 53.9 53.9 D835Y W288fs
179223 No Yes 82 F W M2 normal 53 1.4 25 Dead 1.5 1.5 W288fs
202127 No Yes 68 F W M3 t(15;17) 85 44.2 32 Dead 1.0 1.0 ITD
254137 No Yes 31 F W M2 normal 63 12.6 45 Dead 6.6 6.6
598bp@in@frame@insertion@
AGSSDNEYFYVDFREY
W288fs
321258 No Yes 31 F W M3 t(15;17) 40 1.6 0 Alive 64.3 64.3
327733 No Yes 32 F W M1 normal 94 5.1 70 Dead 11.9 56.3 R132C W288fs
400220 No Yes 34 F W M4 normal 71 19.6 58 Dead 8.3 10.7 MLL.PTD@exon4Hexon7 ITD
455499 No Yes 29 F H M3 t(15;17) 85 1.2 1 Alive 37.1 37.1
501944 No Yes 40 F W M3 t(15;17),+8 90 0.4 0 Alive 73.6 73.6
673778 No Yes 53 M W M3 t(15;17) 42 1.0 29 Alive 76.1 76.1
702808 No Yes 75 F W M5 normal 41 78.1 0 Dead 5.3 6.3 R882H missense W288fs
753374 No Yes 29 M W M2 normal 45 2.2 9 Dead 8.9 11.9 W288fs
758168 No Yes 25 F W M3 t(15;17) 93 16.3 40 Dead 31.6 49.8
804168 No Yes 53 M W M1 normal 86 99.8 52 Dead 7.7 30.0 ITD W288fs
849660 No Yes 22 M W M1 normal 71 167.5 90 Dead 7.7 27.0
863018 No Yes 62 M W M3 t(15;17) 82 0.9 11 Alive 69.4 69.4
907786 No Yes 81 F W M5 normal 53 16.8 7 Dead 9.2 9.2
943309 No Yes 35 M W M3
del(7),+8,@
t(15;17)
90 1.5 7 Alive 63.1 63.1 ITD
203 Yes No 77 M W M0 normal 67 92.0 56 Dead 11.6 18.5 R140Q
245 Yes No 68 F W M1 +21@only 91 3.1 55 Dead 4.9 4.9 R140Q
287 Yes No 64 F W M3 normal 60 116.5 N/A Dead 1.7 2.2 R882H missense ITD W288fs
295 Yes No 76 F B M2 not@done 48 61.6 88 Dead 1.3 1.3 R140Q W288fs
100232 Yes No 81 M W M2 complex 46 1.5 0 Dead 1.4 1.4 R882C missense
150288 Yes No 51 M B M1 normal 62 1.5 10 Alive 13.9 21.3
186481 Yes No 57 F W M4 normal 90 110.2 84 Dead 5.1 7.5 R882C missense D835 R132H W288fs
208027 Yes No 62 F Asian M2 1@cell@+7 46 75.2 53 Dead 6.9 10.2 R803S missense D835 W288fs
237983 Yes No 59 M W M2 H7@only 70 11.5 48 Alive 23.1 23.1 R140Q
245450 Yes No 63 M W M4 +8,H17 62 33.3 9 Dead 8.4 8.4 R729W missense
274429 Yes No 64 M W M1 +8 60 1.2 5 Dead 27.4 27.4 R132C R172K
290344 Yes No 49 F W M4 +11 51 12.4 5 Alive 39.8 39.8 R882C missense
303642 Yes No 54 F W M1 normal 72 17.8 90 Alive 16.2 16.2 R132C W288fs
311636 Yes No 64 F W M4 normal 72 131.5 90 Dead 12.1 24.1 R140Q W288fs
319955 Yes No 45 F W M2
1~50dmin,@
der(6)
56 29.4 37 Alive 45.7 45.7
322110 Yes No 60 F W M1 9qh+ 86 11.5 43 Alive 32.9 32.9 ITD R140Q W288fs
329614 Yes No 68 F W M1 normal 90 202.2 91 Alive 4.3 22.0 ITD W288fs
348685 Yes No 55 F W M4 normal 69 38.4 57 Dead 6.3 8.1
369065 Yes No 59 M W M0 normal 61 1.4 2 Dead 17.2 20.2 splice_site@del R140Q
375182 Yes No 57 M W M5 normal 52 99.2 4 Dead 7.8 7.9 R882H missense ITD W288fs
387919 Yes No 57 F W M1 +8 91 19.8 91 Dead 13.3 15.1 D835Y R132C
431799 Yes No 44 F W M1 normal 86 57.0 17 Dead 13.8 24.8 R882H missense W288fs
433325 Yes No 51 F W M2 normal 64 34.5 79 Dead 10.2 16.3 Q515* nonsense W288fs
499862 Yes No 78 M W M4 normal 70 16.8 28 Dead 0.6 0.6
514066 Yes No 35 F W M1 t(8;21) 81 56.6 86 Dead 4.6 8.0
530962 Yes No 76 M W M7 HY 33 3.6 6 Dead 7.2 9.9 W314fs creates@in@frame@stop@at@314
578179 Yes No 88 F W M1 normal 33 2.9 0 Dead 2.4 2.4
594368 Yes No 42 M B M1
complex@@[no@
favorable]
68 10.7 51 Dead 14.9 21.5
R729Q/D618fs@
(e15+2)
missense/adds@
RVLGLGRGLELPWLSLGCGA@before@stop
R140Q
605322 Yes No 43 F B M1 H7@only 87 183.7 91 Dead 4.0 4.0 R132C
606061 Yes No 37 F W M2 normal 52 18.7 33 Dead 8.5 9.3
632729 Yes No 75 M W M2 9qh+ 76 98.2 80 Dead 0.1 0.1 R882C missense ITD
708512 Yes No 65 F W M4
complex@[no@
favorable]
90 48.5 76 Dead 1.9 7.8 R882H missense D835E R132H W288fs
721214 Yes No 41 F W M1 failed 92 151.8 90 Dead 5.7 5.7 R882H missense ITD W288fs
730817 Yes No 66 F W M5 normal 32 78.5 11 Dead 5.9 7.7 Q615fs D835
740266 Yes No 58 M
W/Nat@
Amer
M0
complex@[no@
favorable]
59 56.5 72 Alive 32.6 32.6 R882H missense R132H
766126 Yes No 60 F W M0 normal 50 2.1 14 Dead 13.8 13.8
851929 Yes No 69 F W M1 +8 42 10.1 32 Alive 24.8 24.8 R792H/R803fs
missense/fusion@of@e20:e22,@fs@adds@
SSAK@before@stop
R172K
868442 Yes No 52 M W M4 normal 75 329.2 51 Alive 16.7 16.7 R882H missense D835Y W288fs
869922 Yes No 56 F W M2 normal 60 202.7 96 Dead 9.6 16.4 R882H missense
914247 Yes No 67 M W M4 normal 30 34.2 6 Dead 18.1 18.1 MLL.PTD@exon3Hexon11 R140Q
957664 Yes No 76 M W M5 +8 78 4.0 0 Dead 0.6 0.6 Q615* nonsense W288fs
972783 Yes No 71 M W M0 +13 90 1.0 13 Dead 13.4 15.4 R140Q
987523 Yes No 27 M B M1
complex@[no@
favorable]
77 277.7 88 Dead 3.0 10.5 R132C
104851 No No 25 F B M2 normal 53 140.1 87 Dead 7.3 11.5 ITD
195182 No No 63 M W M2 H7,t(9;22) 57 77.3 70 Dead 9.3 9.3
242129 No No 51 F B M4
complex@[no@
favorable]
39 61.4 39 Alive 3.7 51.6
t(11;19)(q23;p13.1):@
FISH+
255108 No No 61 M W M0 +8 95 61.6 86 Alive 6.1 52.6 ITD W288fs
255421 No No 47 F W M1 +8@only 77 105.3 79 Dead 6.0 7.4
296361 No No 31 F W M5 normal 83 249.7 6 Dead 6.4 7.5 R882H missense ITD W288fs
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UPN
NanoString,
data WGS Age Sex Race FAB Cytogenetics
%BM,
Blast
PB,WBC@,
presentation
%PB,
Blast
Vital,
Status,,
(4.29.11)
EFS,
months,,,,
(4.29.11)
OS,
months,
(4.29.11) MLL,status DNMT3A DNMT3A,mutation,consequences FLT3 FLT3,other, IDH1, IDH2, NPM1,
303818 No No 41 F W M0
complex1[no1
favorable]
42 47.6 74 Alive 39.0 52.6
312340 No No 33 M W M2 de(9),del(20) 33 2.8 0 Dead 5.7 8.8
325028 No No 44 M W M2
complex1[no1
favorable]
39 34.8 83 Dead 5.2 11.8
326772 No No 47 F W M2
complex1[no1
favorable]
37 12.0 0 Dead 12.2 12.2
332131 No No 24 M W M1 normal 77 223.8 76 Dead 9.8 20.5 G8S ITD
345701 No No 48 F W M1 inv(16) 75 72.9 41 Alive 8.8 26.6
380949 No No 59 F W M5 normal 95 12.1 0 Dead 11.4 11.8
407992 No No 33 M W M4
t(11;19),1
inv(12)
71 25.9 14 Dead 7.7 7.7
t(11;19)(q23;p13):1
FISH+
D835
432398 No No 67 M W M2
complex1[no1
favorable]
50 2.1 17 Dead 10.3 12.4 add(11q23)
434640 No No 71 M W M0
complex1[no1
favorable]
97 5.4 54 Dead 4.8 7.0
470690 No No 58 M W M4 i(17),+13 79 110.3 64 Dead 4.6 4.6
498463 No No 60 F W M1
del(7)(q11.2)1
only
87 46.5 65 Dead 4.9 17.4 P718L missense
537782 No No 51 F W M3 t(15;17) 93 3.6 40 Dead 5.4 46.5
569053 No No 77 M W M6 del(20) 75 2.6 8 Dead 3.7 6.3
619751 No No 57 F W M4 inv(16) 61 13.6 17 Dead 10.8 45.8
671473 No No 42 F W M4 inv(16) 40 37.9 16 Alive 9.8 53.5
723101 No No 65 M W M1
normal1only1151
metaphases
79 143.2 84 Dead 2.7 6.6 MLL.PTD1exon3Vexon11
737451 No No 21 F W M5 normal 90 103.7 72 Dead 7.5 7.5 R882H missense W288fs
806794 No No 70 F W M1 pending 32 0.7 6 Dead 4.2 4.2
809653 No No 60 F W M1
complex1[no1
favorable]
62 16.0 29 Dead 1.9 1.9
852559 No No 18 M W M1
complex1[no1
favorable]
86 144.2 90 Dead 6.7 7.2
861663 No No 48 M W M0 pending 92 72.6 87 Dead 2.4 2.4
868231 No No 63 M W M4 normal 82 76.7 39 Dead 5.3 5.3 ITD
884262 No No 54 M W M6
complex1[no1
favorable]
30 2.3 0 Dead 6.5 10.0
923966 No No 61 M W M5 t(9;11) 89 286.0 0 Dead 3.2 5.7 t(9;11)(p22;q23)
992966 No No 67 M W M1 normal 89 30.8 61 Dead 4.5 5.5 MLL.PTD1exon4Vexon7 R140Q
104 No No 50 M W M4 normal 88 16.9 52 Dead 8.7 12.0 R882C missense R132H
110 No No 61 F W M3 t(15;17) 44 1.0 N/A Dead 24.1 25.7
201 No No 30 M W M3 normal 82 5.7 N/A Alive 57.2 113.1
237 No No 46 M W M1 t(8;7;21) 90 47.7 81 Dead 16.1 30.6
269 No No 23 M W M2 +y 59 32.4 N/A Alive 10.0 103.9
296 No No 81 M W M4 normal 98 90.6 37 Dead 8.2 8.2 R882H missense D835 W288fs
115225 No No 22 M Asian nc normal 80 174.8 94 Alive 15.0 15.0 597bp1in1frame1ins
123804 No No 61 F W M5
+5(5)t(2;5),1
t(8;16)
71 29.6 55 Dead 0.0 0.0 D835H
128392 No No 65 M W M0
complex1[no1
favorable]
83 0.9 0 Dead 17.1 17.1
141273 No No 64 F B M2 normal 80 2.6 46 Alive 15.6 19.2
No1
coverage
No1coverage
No1
coverage
No1
coverage
146218 No No 76 M W M1 inv(16) 73 98.2 55 Dead 4.5 4.5
147796 No No 78 M W M4
complex1[no1
favorable]
40 9.9 6 Dead 1.3 1.3
150951 No No 39 F W M0 del(5)1only 75 2.3 4 Dead 22.2 26.3
156704 No No 49 M W M4 inv(16) 81 105.6 48 Dead 14.2 26.3
179016 No No 42 M B M31
complex1[incl:1
t(15;17)]
88 2.1 2 Alive 32.2 32.2
180168 No No 51 F W M5 normal 57 177.8 0 Alive 20.4 20.4 R882H missense
193139 No No 73 F W M2 complex 32 15.1 11 Dead 0.5 0.5
258135 No No 22 F W M2 inv(16),1t(3;3) 55 51.8 70 Alive 41.1 41.1
263578 No No 52 F W M2 t(8;21) 67 4.1 18 Alive 95.2 95.2
269542 No No 76 M B M0
complex1[no1
favorable]
74 14.5 82 Dead 0.3 0.3
275382 No No 65 M W M0 +8 99 2.9 34 Dead 32.3 32.3 R882H missense
275786 No No 43 M W M2 t(8;21) 40 4.3 39 Alive 19.1 19.1 ITD
291696 No No 61 F W M3 t(15;17),+mar 73 86.4 68 Dead 0.2 0.2 ITD
294154 No No 44 M W M5 normal 74 8.8 5 Dead 0.3 0.3 R736H missense W288fs
318433 No No 55 M W M4 t(2;4),inv(16) 35 22.2 8 Alive 87.6 87.6
327929 No No 50 M B M6 failed 70 5.5 0 Dead 3.7 8.9
346190 No No 64 F W M4 +i(11)(q10) 85 2.9 22 Dead 8.1 8.1 MLL.PTD1exon3Vexon11 R882P missense
399253 No No 77 M W M4 normal 80 40.4 2 Dead 9.3 15.8 R882H missense
400830 No No 73 F W M2 V7 37 1.7 16 Dead 11.0 11.0
405655 No No 83 M W M0 normal 75 93.9 74 Dead 0.1 0.1 ITD1
410324 No No 60 M W M5
complex1[no1
favorable]
94 6.7 30 Alive 36.4 36.4 del(11)(q23);1FISH+
412761 No No 48 M W M5 normal1on1PB 83 116.2 3 Alive 64.4 64.4 W288fs
418499 No No 35 M W M4 normal 90 52.9 18 Dead 17.0 17.0 W288fs
427366 No No 66 F W M5 normal 90 120.0 7 Dead 0.7 0.7 W288fs
447649 No No 74 M W M3 t(15;17) 51 128.3 Promy Dead 0.7 0.7 ITD
463352 No No 25 M W M2
V
Y,t(8;21),del(9)
72 12.6 50 Alive 17.7 17.7
499294 No No 57 M W M4 inv(16) 40 4.9 0 Alive 21.4 21.4
507202 No No 59 M W M4 normal 75 29.7 17 Alive 16.3 16.3 D835Y W288fs
507696 No No 55 F W M4 inv(16) 52 39.9 59 Alive 22.4 22.4
553863 No No 69 M W M0
complex1[no1
favorable]
60 6.1 22 Dead 0.5 0.5
558395 No No 64 M W M4 del(11)1only 95 2.3 0 Dead 0.3 0.3
570755 No No 63 M W M2 t(11;19) 80 17.0 71 Dead 3.9 3.9
t(11;19)(q23;p13.1):1
FISH+
ITD
593890 No No 35 M W M2 +21 34 38.0 40 Dead 14.6 55.4
595704 No No 67 F W M4 inv(16) 69 37.0 61 Alive 31.7 31.7
617776 No No 62 F W M2 normal 72 27.7 49 Dead 4.8 7.1 NULL deleted
633734 No No 53 M W M1 del(7)(q21q36) 72 2.7 41 Dead 19.3 52.7
635258 No No 62 M W M5 normal 85 101.8 22 Alive 30.4 30.4 W288fs
670224 No No 62 M W M4 normal 65 104.1 65 Dead 13.4 14.5 W288fs
690397 No No 45 M W M5 t(6;11) 95 5.1 6 Dead 6.6 6.6 t(6;11)(q27;q23);1FISH+
692900 No No 39 M W M0
+del(5)q,1
t(10;11)
83 5.0 53 Alive 86.1 86.1
717456 No No 50 F W M5 V7,t(9;11) 81 6.7 10 Dead 5.6 5.6 t(9;11)(p22;q23);1FISH+
729805 No No 66 M W M4 complex 81 2.2 12 Dead 1.6 1.6
750152 No No 34 F W M2 t(8;21) 57 14.3 59 Alive 34.8 34.8
757199 No No 50 F W M3
t(15;17),1
t(16;19)
90 3.4 0 Alive 19.8 19.8
767969 No No 72 M W M1 complex 88 37.5 18 Alive 27.0 27.0
794178 No No 73 M W nc complex 90 58.9 0 Dead 0.2 0.2
807615 No No 51 M W M1 normal 85 103.6 85 Dead 3.1 3.1 R882H missense ITD
826984 No No 51 F W M4 t(5;21) 73 2.9 2 Dead 8.0 11.1
862507 No No 55 F Unk M4 del(16),+22 54 114.5 24 Alive 61.3 61.3
866660 No No 41 M W M2 pending 47 148.4 62 Alive 13.4 13.4
905179 No No 75 F W M2 t(8;21),1del(9) 48 8.3 54 Dead 18.2 19.2
938150 No No 60 F W M7
complex1[no1
favorable]
58 0.8 0 Dead 12.0 13.6
944281 No No 31 M W M4 inv(16) 82 336.8 53 Alive 20.1 20.1 D835Y
962561 No No 76 F W M4 +13,V21 37 2.7 0 Dead 17.3 22.3
964886 No No 33 F B M3 normal 100 0.9 0 Alive 69.0 69.0 ITD
974749 No No 63 M W M1 +8,1+8 81 46.4 97 Dead 1.2 1.2 R882H missense R132C
982009 No No 70 M B M1 normal 84 282.4 49 Dead 4.9 6.3 D835Y W288fs
986000 No No 77 M W M7
complex1[no1
favorable]
47 1.9 0 Dead 4.5 4.5
989176 No No 76 F W M1 normal 99 352.3 98 Dead 0.4 0.4 W288fs
997292 No No 66 F W M2 normal 70 3.4 6 Dead 5.2 5.2 K468R,K829R missense/missense R132C
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Table 2-2. Somatic mutations within HOX clusters identified by whole genome 
sequencing of 45 de novo AML patients. 
 
 
 
 
 
  
Patient 831711 849660 863018 179223 246634 246634 775109 869586 501944 943309
Chromosome7
Position
7:2720780
7
12:525190
96
17:439558
04
7:2729621
1
12:525770
61
12:526464
01
12:525882
42
17:441567
25
17:441571
10
17:441432
38
Reference A C A G C T C G T A
Variant G T G T T G T T C C
Nearest7HOX7
gene
HOXA13 HOXC13 HOXB1 HOXA13 HOXC13 HOXC11 HOXC13 HOXB13 HOXB13 HOXB13
Distance7(C)7
up7or7(+)7
downCstream7
of7TSS
41,586 499,862 6,104 489,990 441,897 46,892 430,716 2,426 2,041 15,913
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Table 2-3. Expression correlation values for pairs of HOX genes. 
 
 
 
 
 
  
Gene$Pair r^2$Value p$value
A5#v#A9 0.6908 < 0.0001
A5#v#A10 0.7369 < 0.0001
A5#v#B2 0.3584 < 0.0001
A5#v#B3 0.5828 < 0.0001
A5#v#MEIS1 0.4878 < 0.0001
A9#v#A10 0.7173 < 0.0001
A9#v#B2 0.4877 < 0.0001
A9#v#B3 0.5194 < 0.0001
A9#v#MEIS1 0.5165 < 0.0001
A10#v#B2 0.5079 < 0.0001
A10#v#B3 0.5671 < 0.0001
A10#v#MEIS1 0.4121 < 0.0001
B2#v#B3 0.7165 < 0.0001
B2#v#MEIS1 0.5167 < 0.0001
B3#v#MEIS1 0.6758 < 0.0001
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Table 2-4. Orthogonal validation of AffyMetrix U133 Plus 2 Array data with custom 
NanoString codeset 
 
 
Probe Mean Std Dev Target Sequence Mean
Std 
Dev |r| p value
HOXA1 214639_s_at 552.90 468.23 ATAATTCTGGACCAGAGACTTGGTGCGGGGTTAACACCTTCATCCAGATTGGGTGCCAGCATACATTTTCTGGTGGGCCTTAACATCCCTCCTGCTTTTA 29.98 27.55 0.78 <0.0001
HOXA2 214457_at 355.40 267.12 CCCAAAGTTTCCCAGTCTCGCCTTTAACCAGCAATGAGAAAAATCTGAAACATTTTCAGCACCAGTCACCCACTGTTCCCAACTGCTTGTCAACAATGGG 41.98 40.36 0.70 <0.0001
HOXA3 235521_at 2989.00 4510.00 CCTGGTCTCCTCCGGGGATGCTTCGCGGTCTGTTATCGCGTCAGGAGGAAAGAATTGCTCCAAAAATCTGCACGCGGAGCGAAACAGTTTGAAAGGGACT 24.02 24.06 0.38 <0.0001
HOXA4 206289_at 1335.00 1204.00 TGCACTTCACAAATTAATGACCATGAGCTCGTTTTTGATAAACTCCAACTACATCGAGCCCAAGTTCCCTCCCTTCGAGGAGTACGCGCAGCACAGCGGC 101.57 109.74 0.76 <0.0001
HOXA5 213844_at 10813.00 10452.00 CATAGTTCCGTGAGCGAGCAATTCAGGGACTCGGCGAGCATGCACTCCGGCAGGTACGGCTACGGCTACAATGGCATGGATCTCAGCGTCGGCCGCTCGG 525.47 770.29 0.83 <0.0001
HOXA6 208557_at 916.12 848.96 CGCGCTGAGGCCCTTCCCGGCCTCGTACGGGGCGTCGAGTCTCCCGGACAAGACGTACACCTCACCTTGTTTCTACCAACAGTCCAACTCGGTCCTGGCC 462.36 648.99 0.67 <0.0001
HOXA7 235753_at 2229.00 1894.00 CGTATTATGTGAACGCGCTTTTTAGCAAATATACGGCGGGGGCTTCTCTGTTCCAAAATGCCGAGCCGACTTCTTGCTCCTTTGCTCCCAACTCACAGAG 198.35 183.51 0.66 <0.0001
HOXA9 209905_at 18241.00 15137.00 AACCGCCATTGGGCTACTGTAGATTTGTATCCTTGATGAATCTGGGGTTTCCATCAGACTGAACTTACACTGTATATTTTGCAATAGTTACCTCAAGGCC 629.17 615.53 0.80 <0.0001
HOXA10 213150_at 4581.00 4823.00 GGGGTAAGCGGAATAAACTAGAGAAGGGAGACATTGTTTGGATTTCCTTTATACTGTGAAGTTACATGCATAAAAGGGTCAAACCTGTAGATGCAGAAAA 342.71 304.35 0.69 <0.0001
HOXA11 213823_at 311.42 667.80 TGGAGGTAGCTTTGAGGTGGAAGAGGGCTGCAAATCCTTGTGGGAAAAGAAATCTATGATTCCAGGTGGCATCAGTGTCTTTCCACTCCTCCTAGCCACC 20.11 40.06 0.39 <0.0001
HOXA13 231786_at 69.40 138.30 GAGTCGCGCCACGAACCCTTGGGTCTTCCCATGGAAAGCTACCAGCCCTGGGCGCTGCCCAACGGCTGGAACGGCCAAATGTACTGCCCCAAAGAGCAGG 7.92 13.62 0.25 0.0388
HOXB1 208224_at 225.36 194.16 GGGAACGAGCAGACCGCGAGCTTTGCACCGGCCTATGCTGATCTCCTCTCCGAGGACAAGGAAACACCCTGCCCTTCAGAACCTAACACCCCCACGGCCC 6.53 9.36 0.15 0.2155
HOXB2 205453_at 4628.00 3038.00 GAATTCCACTTTAATAAGTACCTGTGCCGGCCACGCCGCGTCGAGATCGCGGCCTTGCTGGACCTCACCGAAAGGCAGGTCAAAGTCTGGTTTCAGAACC 236.30 215.92 0.78 <0.0001
HOXB3 228904_at 8111.00 12274.00 TGTCCGTTTAAATGCTGCTGGGAGACTCGTAAAAAAATCATCGTGGACCTGGAGGATGAGAGGGGCGAGCTTTATTTCGGTCGGATTGCGGTGTGGTGGT 225.18 242.70 0.57 <0.0001
HOXB4 231767_at 1810.00 1464.00 CCTTTCTTTGTCCCCCACTCCCGATACCCAGCGAAAGCACCCTCTGACTGCCAGATAGTGCAGTGTTTTGGTCACGGTAACACACACACACTCTCCCTCA 551.54 551.18 0.85 <0.0001
HOXB5 205600_x_at 1516.00 1017.00 GCTTGTAAATATGGGGATAGTCTGGGTCAGACCCATCTCTCCCTTACCCATCTTGCTTCCAAGACCATTTGTAGTGAGCGAGTGGATGCTGTGCTACGTG 81.30 83.36 0.81 <0.0001
HOXB6 205366_s_at 1293.00 1968.00 CACCCATTCCTTTAAATCCGGAGGGGGAAAAAATCCCAAGGTCTGCAAAGGCGCGGCGCTCGGACTATAAAACACAACAAATCATAAACCCGGCGGAGCA 6.73 12.53 0.04 0.6165
HOXB7 216973_s_at 964.03 2011.00 AAATCTGGACTCTAATTCTGTAATATATCAAGGAATCTCGTAAAACCGACACTAAAACGTCCCTGCCTACAAATCATCCGGCCAAATTATGAGTTCATTG 24.04 38.16 0.71 <0.0001
HOXB8 229667_s_at 425.76 1488.00 GTGGTAGTATCTCGTAATAGCTTCTGTGTGTGAGCTACCGTGGATCTCCTTCCCTTCTCTTGGGGGCCGGGGGGAAAGAAAAGGATTTAAGCAAAGGCTC 125.02 367.07 0.28 <0.0001
HOXB9 216417_x_at 711.26 1010.00 GGTGGCTGTCGTGAAATTGTGCTTGTGTTTCGTGATTTCTTTGGGGGTGATTGTCTCGCTTGTTTTCAGTTGTCGATTATATGGGAGGGTTCTGGGTGGG 61.43 110.61 0.40 <0.0001
HOXB13 209844_at 44.28 36.86 CCACCAGGGTTCCCAAAGAACCTGGCCCAGTCATAATCATTCATCCTGACAGTGGCAATAATCACGATAACCAGTACTAGCTGCCATGATCGTTAGCCTC 9.33 27.23 0.04 0.674
HOXC4 206194_at 456.66 273.31 AGCGCCGCCAGCAAGCAACCCATAGTCTACCCATGGATGAAAAAAATTCACGTTAGCACGGTGAACCCCAATTATAACGGAGGGGAACCCAAGCGCTCGA 4.75 8.61 0.38 0.0012
HOXC5 206739_at 180.67 147.88 CAGACTCTGGAACTCGAGAAAGAATTCCACTTTAACCGCTACCTCACTCGCCGCAGGCGCATAGAGATCGCCAACAACTTGTGTCTCAATGAGAGACAGA 6.65 11.63 0.03 0.8162
HOXC6 206858_s_at 424.56 1628.00 ACGTCGCCCTCAATTCCACCGCCTATGATCCAGTGAGGCATTTCTCGACCTATGGAGCGGCCGTTGCCCAGAACCGGATCTACTCGACTCCCTTTTATTC 9.24 14.97 0.14 0.2589
HOXC8 221350_at 285.96 173.97 ACAGCCGGTATCAGACCTTGGAACTAGAAAAGGAGTTTCTCTTTAATCCTTATTTGACACGAAAACGTCGGATTGAAGTCTCTCATGCCCTGGGACTGAC 7.59 13.13 0.17 0.1584
HOXC9 231936_at 102.22 205.04 AATAATCTTATGTATGTAAAACCCCGTTACGATGTCGGCGACGGGGCCCATCAGTAACTATTACGTGGACTCGCTCATCTCTCACGACAATGAAGACCTC 5.57 7.70 0.13 0.2898
HOXC10 218959_at 267.38 280.67 GGAAAGTTCGGCTAGTGTTCGTGTGTTTGTCGTAGCACCCAGAGCCTCCACCAAACCCTCTCCATGTCTTTACCTCCCAGTCGCTCTAAGAATCTGCTTG 10.03 35.61 0.02 0.8763
HOXC11 206745_at 370.68 213.39 GGCGACAGTAGTGAGCGCCTGAGCCGAACAATCCTCGAACTAAAAGCCTTCCCTTGCCCATGTGAAAAGATCCGCTAAGACAGCATGTCTGCCAGCGGAA 7.30 4.38 0.08 0.5301
HOXC12 1553512_at 165.49 126.57 AGGGAACTCTCAGACCGCTTGAATCTTAGTGACCAGCAGGTCAAGATCTGGTTTCAGAACCGGAGAATGAAAAAGAAAAGACTTCTGTTGAGGGAGCAAG 17.50 10.88 0.13 0.2889
HOXC13 219832_s_at 69.82 77.52 ACTCCTCACACTTTCACCTTTACTGATTTCCAGAGGAAAGCTAGAGGATCTAGTTCAAGAGGCAAGAAGATCTGGCCCTCAATTAGCTAGATGTAGATGC 11.44 7.79 0.01 0.904
HOXD1 205975_s_at 245.71 213.15 CTCCCGCCTCCGGCCTCCCTGCCGCCTTCAGCACGTTCGAGTGGATGAAAGTGAAGAGGAATGCCTCTAAGAAAGGTAAACTCGCCGAGTATGGGGCCGC 2.65 7.43 0.05 0.5479
HOXD3 206602_s_at 84.47 100.38 TAAAGGATTAAGACCGCAAATTGTCCTTCATGGGTAGAGTCAGGAAGCCCGGTGGCGTGGCACAACACACTTTGGTCATTTCTCAAAAACCACAGTCCTC 4.82 5.23 0.04 0.5976
HOXD4 205522_at 132.27 117.52 TGTGAAAATTATGAGATGCTCACCAACCCGGTGATAAACTTGCTCCCTCGCCATTGGCTGGCCTGGTCACATGGCTGCCCAACTTTATTCAGTTGACAGC 9.23 7.18 0.20 0.017
HOXD8 231906_at 294.16 145.46 TTACGGATACGATAACTTACAGAGACAGCCGATTTTTACGACCCAGCAAGAGGCCGAGCTGGTACAATATCCTGACTGTAAATCGTCCAGTGGTAATATT 6.44 7.82 0.14 0.2509
HOXD9 205605_at 158.68 137.55 TTTGGGGTTTCGCCCTATCCCACTCCCTCTCTTTCCTGCTCCATTGGTTCCTTAAGAAATGCTATATTTTGTGAGTGCAAGCTGGCTTGGGGAGCCCTCT 6.34 18.96 0.02 0.8303
HOXD10 229400_at 110.40 131.04 TCCCGTCTCTGGCCAAAAGAGAAGTGAACCACCAAAATATGGGTATGAATGTGCATCCTTATATACCTCAAGTAGACAGTTGGACAGATCCGAACAGATC 8.24 21.62 0.05 0.5245
HOXD11 214604_at 128.39 118.90 CAGCCTGCTCTCCGCAGGCCCACTGTCCTTGGGTTTAATGACGTCTCTTCTCTGTGGAACTTCACGATTCCTTCCCACGGTCAACTCGGGACCTCCCAGC 2.49 2.07 0.13 0.2868
HOXD13 207397_s_at 70.71 90.44 GGTAATTGAATCATTAGCTCTCAGCAGTTGCCCTGAGGCAAGTGGAAAGGCAGGCAGTGCTCTGGGGTCACCGAGAAAGTCTAAAAACAGGAGGCTGAAG 3.14 5.55 0.02 0.7586
Gene
Affymetrix U133+2 NanoString Spearman Correlation
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Genetic heterogeneity of murine induced pluripotent stem (iPS)  
clones revealed by whole genome sequencing 
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Abstract 
Use of integrative techniques for reprogramming of somatic cells into induced pluripotent 
stem (iPS) cells has led to concerns for their genomic integrity. Here we performed whole 
genome sequencing of 10 murine iPS lines produced in 3 independent experiments. 
Several hundred somatic nucleotide variants (SNVs) were identified in each clone, an 
average of 11 in protein-coding regions. The variant allele frequency of the first 2 
experiments shows that the majority of SNVs are present in 50% of the reads, suggesting 
three possibilities for when these mutations could have arisen: 1) prior to reprogramming, 
2) in a single burst at the time of reprogramming, or 3) in a burst after reprogramming 
leading to a selective advantage during expansion. In the third experiment, all four iPS 
lines contained 164 identical variants (6 protein-coding SNVs, 157 non-coding SNVs and 
1 structural variant), as well as an average of less than 100 “private” SNVs unique to 
each clone. The common mutations were found in a subpopulation of the parental cells, 
proving that they were present before reprogramming. This suggests that one or more of 
these mutations may have been relevant for reprogramming fitness. For the private 
mutations, in addition to the majority of SNVs showing a 50% variant allele frequency, 3 
of the clones have a subclone with variant allele frequencies of 20-30%. These subclones 
may represent acquisition of variants that have given a selective growth advantage to 
individual cells during post-reprogramming expansion. Our data suggest that most of the 
mutations detected in iPS cells occurred prior to reprogramming and are simply 
“captured” by cloning; however, some preexisting mutations provide an advantage for 
reprogramming, and may provide novel insights into the genetic underpinnings of this 
process. 
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Introduction 
The discovery of methods to produce induced pluripotent stem (iPS) cells in 2006 has 
revolutionized the field of regenerative medicine.  Yamanaka, et al. and Thomson, et al. 
showed that expression of a small set of transcription factors in mouse or human somatic 
cells is capable of reprogramming them to a pluripotent state [1-3]. Since then, there have 
been successful modifications of the reprogramming protocol that have decreased safety 
concerns, and increased the efficiency of the process. Reprogramming is now possible 
without the use of c-myc [4-6], and can be performed with single lentiviruses to limit 
integration dependent mutagenesis [4, 7, 8]; reprogramming has also been performed by 
transiently expressing specific cDNAs, RNA molecules, or proteins themselves [9-12]. 
Addition of demethylating agents and histone deacetylase inhibitors has also been shown 
to enhance iPS cell generation [5, 13, 14].  
 
iPS cells provide novel models for the study of human diseases, and gene-corrected iPS 
cells may provide novel therapeutic reagents [15-17]. Daley and colleagues were the first 
to generate a panel of iPS lines from a variety of patients with complex diseases with 
genetic components, including Huntington’s Disease (HD), Parkinson’s Disease (PD) and 
juvenile-onset type I diabetes mellitus (JDM) [18]. Ellerby, et al. have been able to 
generate striatal neurons from the HD-iPS lines, which have the potential to be used for 
drug screening [19]. Since the Daley report, iPS lines have been generated from patients 
with a wide range of disorders [16, 20-29]. Jaenisch and Townes provided a proof of 
principle study in which they rescued a humanized sickle cell anemia mouse model by 
transplanting gene-corrected iPS cells that had been induced to undergo hematopoietic 
	   88	  
differentiation [15]. Most recently, Cantz et.al. generated mice from tetraploid embryo 
aggregations of gene-corrected  iPS cells, proving that genetic manipulation does not 
diminish the pluripotent phenotype of iPS cells [30].  
 
Although advancements have been made in the generation of iPS cells, the mechanism 
behind reprogramming is not completely understood.  Yamanaka proposed 2 potential 
models of reprogramming: “elite” vs. stochastic [17]. According to the elite model, 
reprogramming is inefficient because only a tiny fraction of cells within the donor pool 
are competent (or “fit”) for reprogramming; perhaps less-differentiated cells within a 
heterogeneous population are more readily transformed than their fully differentiated 
counterparts. In contrast, the stochastic model suggested that all cells are equally capable 
of being reprogrammed with the correct balance of reprogramming factors. The 
stochastic model suggests that reprogramming is a purely epigenetic phenomenon. 
Reprogramming has also been shown to require new methylation patterns that 
presumably reflect the activation of endogenous pluripotency genes, and repression of 
differentiation genes from the parental cells. Ecker and colleagues defined the 
methylomes of iPS lines at single base resolution, and found that although they are 
globally similar to ES cells, iPS cells have regions of unique methylation [31]. Perhaps 
surprisingly, then, reprogramming of fibroblasts deficient in Dnmt3A and Dnmt3B (the 
de novo methyltransferases responsible for methylation in ES cells) revealed that neither 
of these genes are required for reprogramming [32]. This information, coupled with the 
fact that iPS cells have “memory” of the parental cells from which they were derived 
[33], suggests that there may be additional factors at play in iPS cell generation. 
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The genetics of iPS clones has been less well studied. Early, low-resolution studies 
showed that iPS lines generally have normal karyotypes [1, 3, 34, 35]. However, more 
recent analyses of iPS genomes suggest that there may be more subtle genetic 
consequences of reprogramming. Hall’s group used whole genome sequencing data to 
detect structural variants (SVs) in 3 iPS lines derived from a single reprogramming 
experiment. They found a very small number of new SVs in the iPS lines, suggesting that 
reprogramming is not detrimental to genome stability [36]. Gore, et al. performed whole 
exome sequencing of 22 human iPS lines generated with multiple transcription factor 
delivery protocols in many different labs, using a variety of donor cell types. They 
detected an average of 5 non-synonymous point mutations per genome analyzed, which 
were enriched in genes found in the COSMIC database of cancer-associated genes [37, 
38]; the authors concluded that iPS cell genomes often contain mutations that may be 
related to cancer pathogenesis, raising an important safety issue if these cells are to be 
used therapeutically.  
 
In this study, we performed comprehensive whole genome sequencing to define all 
genetic events associated with reprogramming. We analyzed 10 murine iPS lines 
generated in 3 separate experiments. A polycistronic lentivirus was used for 
reprogramming, so that we could track integration events and genetically define each 
clone as unique. We found that all reprogrammed iPS lines have a set of several hundred 
mutations that are unique for each clone, with variant allele frequencies of ~50% for 
nearly all mutations. In one of the three experiments, however, each clone tested was 
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found to have a set of common mutations, along with a larger set of unique mutations; all 
of the mutations had variant allele frequencies of ~50%.  These data strongly suggests 
that the MEF pool from which these cells were derived contained a tiny set of cells that 
were extraordinarily “fit” for reprogramming, probably due to the effects of one or more 
of the common mutations. The mutations found in the 10 iPS clones were not enriched in 
the COSMIC database. In sum, our data suggests that most mutations in iPS cells are 
random and benign, occurring during the growth and development of the fibroblasts that 
gave rise to each iPS clone.  The mutational “footprint” of the fibroblasts that are 
reprogrammed are “captured” by the cloning event itself.  Preexisting mutations in 
somatic cells should be captured by any reprogramming strategy during the cloning 
process; clearly, some may be relevant for reprogramming fitness. By sequencing large 
number of iPS clones, pathways that faciliate fitness may become evident, and 
exploitable to improve reprogramming efficiency and safety. 
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Materials and Methods 
Production of iPS clones 
We generated iPS clones from 3 parental cell lines: 1) wildtype mouse embryonic 
fibroblasts (MEFs), 2) wildtype tail tip fibroblasts (TTFs), 3) GusB -/- MEFs. iPS clones 
were generated from each line as previously described [4]. Briefly, 3x105 of each cell 
type were seeded on 6 well plates and allowed to grow overnight. The next day, the cells 
were transduced with the OSK lentivirus (kindly provided by Tim Townes) at an MOI of 
1-5. The cells were incubated with virus for 48 hours then trypsinized and transferred to a 
100-mm dish without a feeder MEF layer. Cells were grown for 2-3 weeks with daily 
media changes. After 17-26 days (see Table 3-1) individual colonies were picked and 
expanded on MEF feeder layers.  
 
Pluripotency characterization of iPS clones 
All 10 iPS clones were assessed for ES cell-like morphology and stained for alkaline 
phosphatase according to the manufacturer’s instructions (Millipore?). Cells were 
analyzed by flow cytometry for ES cell markers, SSEA-1, Nanog and Oct4. For 
intracellular Nanog and Oct4 detection cells were fixed with 4% paraformaldehyde and 
permeabilized with 1% saponin. In addition to these basic assays, the 4 clones from the 
third experiment underwent further analysis.  
 
Total RNA comparison of ES cells vs. iPS cells. RNA was analyzed on the Mouse Exon 
1.0 ST array (Affymetrix, Santa Clara, CA) as previously described [39]. Briefly, 100 
individual colonies of each clone and ES cell controls were picked and RNA was purified 
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using TRIzol (Invitrogen, Carlsbad, CA) and amplified using the whole transcript WT-
Ovation RNA Amplification System and biotin-labeled (NuGen Technologies, San 
Carlos, CA) (each samples prepared in duplicate). Amplified RNA was then applied to 
the Mouse Exon 1.0 ST array according to standard protocols from the Siteman Cancer 
Center, Molecular and Genomic Analysis Core Facility 
(http://pathology.wustl.edu/research/cores/lcg/index.php). Affymetrix Expression 
Console software was used to process array images, export signal data, and evaluate 
image and data quality relative to standard Affymetrix quality control metrics. Spotfire 
analysis software (TIBCO, Somerville, MA) was used for unsupervised hierarchical 
clustering of ES and iPS global RNA levels. For lentivirus insertion site analysis of 
experiment 3 clones, the best probe (defined as the probe with the highest average 
expression level) for each nearest neighbor gene was plotted. 
 
Oct4 and Nanog promoter methylation status. DNA was prepared from 100 individually 
picked clones (to minimize contaminating feeder layer MEFs) using the QIAamp DNA 
Mini Kit according to the manufacturer’s instructions (Qiagen, Valencia, CA). DNA 
samples (1 ug) were then converted with bisulfite using the Zymo Research EZ DNA 
Methylation Kit according to the manufacturer’s instructions (Zymo Resarch, Irvine, 
CA). Bisulfite specific primers were used to amplify the promoter regions of Oct4 (5’- 
TCCAACCCTACTAACCCATCACC -3’ and 5’- GGTTTTTTAGAGGATGGTTGAGTG -3’) and 
Nanog (5’- ACCAAAAAAACCACACTCATATCAATATA -3’ and 5’- GATTTTGTAGGTGGGAT- 
TAATTGTGAATTT -3’) followed by deep digital sequencing on the 454-Flx platform. 
Each CpG dinucleotide was covered by >1000 reads, and the percentage of methylated C 
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residues were determined for each position. 
 
Cystic teratoma formation. NOG mice were injected in the hindflank with 1 million iPS 
cells from each of the four iPS lines. Tumors were harvested after 5-6 weeks of growth 
and sectioned. Sections were H&E stained and analyzed. In all tumors, there were tissues 
of ectodermal, mesodermal, and endodermal origin noted.  Examples of tissues of 
endodermal origin included ciliated pseudostratefied epithelium or columnar epithelium.  
Examples of tissues of mesodermal origin included bone, cardiac muscle, or cartilage.  
Fibrous connective tissue was also noted in some that did not appear to represent native 
tissue.  Examples of tissues of ectodermal origin were components of the nervous system, 
particularly the MPS samples appeared to have abundant tissue representative of 
embryonal brain.  The ES sample contained brain tissue that appeared better 
differentiated.  Some tissues also had components of epidermis. 
 
llumiIna whole genome shotgun library construction.  
We followed the standard library construction procedure as previously described [40]. 
Briefly, we started with 100ng of DNA from each clone and the MEFs. After the DNA 
was fragmented, end repaired, and ligated with adaptors, we amplified the products and 
ran them on a polyacrylamide gel. We then excised gel slices between 300-350 bp and 
450-500 bp for each sample, and eluted the DNA from each gel slice as the source for 
independent libraries. 
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Illumina exome library construction and capture 
Illumina sequencing libraries were constructed according to the manufacturer’s protocol 
(Illumina Inc, San Diego, CA) with the following modifications: 1) DNA was fragmented 
using a Covaris S2 DNA Sonicator (Covaris, Inc. Woburn, MA) to range in size between 
100 and 500bp.  2) Illumina adapter-ligated library fragments were amplified in four 50µl 
PCR reactions for eight cycles.  3) Solid Phase Reversible Immobilization (SPRI) bead 
cleanup was used to remove primers from the PCR and select for 300-500bp fragments. 
Sequencing libraries were hybridized with the SureSelectXT Mouse All Exon Kit 
(Agilent), which captures 49.6 Mb of the coding sequence from ~24,000 genes. KAPA 
qPCR was used to determine the quantity of library necessary to produce cluster counts 
appropriate for the Illumina HiSeq 2000.  
 
Illumina sequencing. 
After diluting the libraries to a 10pM concentration, we utilized the paired-end flow cell 
and cluster generation kits to produce flow cells with an average cluster density ranging 
between 1.9 - 3 million clusters per tile. We employed the standard sequencing kits 
(Illumina HiSeq Sequencing Kit) and performed 100 cycles of nucleotide incorporation. 
Following this first round of end sequencing, the flow cell was treated to remove the 
synthesized fragments, clusters were re-amplified, and the resulting fragments were 
linearized. We then annealed the second sequencing primer, and initiated another round 
of sequencing by synthesis to complete the read pairs. The read length for the second 
sequencing round matched that of the first. Following round two, we utilized an Illumina 
HiSeq 2000 machine and the Illumina sequencing pipeline, version 1.7 or 1.8, to analyze 
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the data and produced files containing high quality (“passed filter”) reads with associated 
quality values. 
 
Clonality analysis 
Sub-clonality estimates were determined using the mutation allele frequencies from 
whole genome sequencing. To minimize the effect of coverage outliers from likely false 
positives, we pre-filtered each site to ensure that the coverage fell within ±2 median 
absolute deviations from the median coverage of all non-repetitive predictions within 
each clone.  We drew a kernel density estimate (KDE) plot for variant allele frequencies 
using the density() function in R. A customized R function evaluated each KDE plot to 
determine the number of significant peaks, which served as an estimation of the number 
and relative composition of different sub-clones present within each iPS clone. 
 
Significantly mutated gene analysis and pathway analysis 
Since the mutational process in clones is analogous to the mutational process of a tumor, 
we used components of the unpublished Mutational Significance in Cancer (MuSiC) 
package to determine significantly mutated genes (SMG) and pathways. The SMG 
component of MuSiC assigns mutations to various categories, such as transition or 
transversion, and then uses methods including convolution, Fisher’s test, and a likelihood 
test to combine the category-specific binomials to obtain an overall P-value. The result is 
appreciably more accurate than if these attributes were disregarded. The pathway analysis 
component of MuSiC is an implementation of PathScan[41].  
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Sequence Analysis 
Reads were aligned using BWA 0.5.5[42] with quality trimming set at 5 to the NCBI 
build 37 of Mus musculus reference sequence augmented with an additional contig 
representing the complete OSK sequence. The resulting alignments were de-duplicated 
using Picard (http://picard.sourceforge.net) and quality recalibrated using the GATK[43] 
base quality recalibrator (v1.0.3471).  
 
We called potential somatic single nucleotide variants using a modified version of 
SomaticSniper[44] to account for perfectly pure samples. Variants with a somatic score 
greater than 10 were filtered on a number of sequence features to remove false positives 
as described elsewhere[45]. Sites passing these filters were additionally filtered to 
remove variants where the difference between the clone and control variant allele 
frequency was 30% or less and the read depth was 10 reads or less. Non-genic variants in 
repetitive regions as identified from the UCSC Genome Browser[46] for mouse build37 
were also excluded from further analysis. Variants passing all filters were annotated as 
previously described[47].   
 
Sites chosen for validation were manually reviewed and validated using 454 sequencing 
as previously described[48]. Read counts were calculated by excluding reads where the 
called base was below a Phred quality of 15 for WGS data, with a mapping quality of 10 
or a base quality less than 20 for the high depth Illumina data, and for a base quality less 
than 20 for the 454 data.  
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Indels were called using the GATK[43]. OSK insertion sites were predicted using 
BreakDancer[49] and SquareDancer, an in-house implementation of the CREST 
algorithm[50]. Copy number predictions were generated as previously described[47] and 
manually reviewed to determine their veracity. 
 
Detection of common variants in parental MPSVII MEFs.  
Rare variants were detected in the parental MEFs by novel StuI sites are generated by the 
Apaf1 G16A and Sbno2 A3783G variants. Regions surrounding each variant were 
amplified (Apaf1: 884 bp amplicon, 5’-CCCAAACACTTTGATGAACGA-3’ and 5;- 
CTATAAGGACCTTGCTGCGC-3’ ; Sbno2: 806 bp amplicon, 5’-GCTGCAGACTGACACA- 
GGAG-3’ and 5’-AGCAGAGGCTCCCATGACTA-3’). PCR products were cloned into the 
pCR2.1 vector according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). 
The number of clones in individual transformations was counted and each plate was 
pooled as a single sample (see Table 3-5 for pool sizes), creating mini-libraries of the 
parental MEFs. These mini-libraries were then digested with EcoRI to extract the 
amplicon from the pCR2.1 vector and StuI to detect the presence of the variant allele 
(Apaf1: 391 and 493 bp products; Sbno2: 454 and 352 bp products). Digestion products 
were run on 5% acrylamide gels and transferred to nitrocellulose. Nitrocellulose blots 
were probed with 32P-labeled probes (Apaf1: the 493 bp product; Sbno2: the 352 bp 
product).  
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Additional MPSVII TTF iPS production and analysis. 
iPS cells were produced from tail tip fibroblasts of an adult MPSVII mouse as described 
above for experiments 1-3. DNA was prepared as described above and the Apaf1 and 
Sbno2 regions were amplified as for the detection of variants in rare parental cells. PCR 
products were directly Sanger sequenced and analyzed for the variant allele. 
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Results 
Experimental system 
 
To investigate the genetic consequences of transcription factor-mediated reprogramming, 
we generated murine iPS lines using a established polycistronic lentivirus encoding three 
of the original four Yamanaka transcription factors, Oct4, Sox2 and Klf4 (OSK) [4]. We 
reprogrammed 3 independent fibroblast lines, all derived from C57Bl/6 mice; wildtype 
mouse embryonic fibroblasts (MEFs) and tail tip fibroblasts (TTF) in experiments 1 and 
2, respectively, and MEFs derived from a disease model (murine mucopolysaccaridosis 
type VII- MPSVII) in the third experiment. Details of cell culture and transduction, 
followed by clone picking and expansion of individual clones, are provided in the 
Materials and Methods, and listed in Table 1. 
 
All clones were examined for morphology and alkaline phosphatase positivity, as well as 
surface expression of the pluripotency markers SSEA-1, Nanog and Oct4. All clones had 
characteristics of pluripotent cells (Table 1). Since experiment 3 utilized MEFs derived 
from a disease model known to have growth and developmental defects (MPSVII, caused 
by a loss-of-function mutation in the GusB gene), we characterized the pluripotency of 
these iPS lines further [51, 52]. The Affymetrix Mouse Exon 1.0ST array was used to 
compare expression patterns in iPS lines and ES cells. Unsupervised hierarchal clustering 
analysis showed that the iPS clones and ES cell lines clustered randomly, suggesting that 
their global expression patterns are highly similar (Figure 1).  The methylation status of 
the Oct4 and Nanog promoters was analyzed by bisulfite modification of genomic DNA 
from each of the four lines, along with ES and MEF controls.  The promoter region of 
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each gene was amplified with bisulfite-specific primers, followed by deep digital 
sequencing on the 454-Flx platform. Each CpG dinucleotide was covered by >1000 
reads, and the percentage of methylated C residues were determined for each position.  
Figure 2 shows that the promoters were extensively methylated in MEFs, but not in ES 
or iPS cells. Lastly, NOG mice were injected in the hindflank with 1 million iPS cells 
from each of the four iPS lines; and line formed cystic teratomas containing all 3 germ 
layers (Figure 3).  
 
Genomic Architecture of iPS Clones 
Genomic DNA from each iPS line and their parental cells were used to make libraries 
that were subsequently sequenced with a paired-end approach on the Illumina GAIIX 
platform. Each sample was sequenced to a depth of 16x haploid coverage; a lower level 
of coverage is required for mutation discovery for inbred organisms (Table 2) [53].  The 
polycistronic OSK lentivirus was used for reprogramming to create genetic marks that 
would define each clone as unique. Indeed, each iPS line had 1-5 unique lentiviral 
insertion sites (Table 2 and Figure 4A).  For experiment 3, we used expression array 
data from each clone to demonstrate that the lentiviral insertions did not detectably alter 
expression of their nearest neighbor genes in any clone or insertion site (Figure 4B).  
 
We first identified homozygous single nucleotide variants (SNVs) in the three parental 
cell lines (with respect to the reference C57Bl/6 genome). Each line had more than 2,000 
homozygous SNVs, many of them within coding regions (Figure 5), illustrating the 
genetic drift that exists among B6 mice over time. This result shows the critical 
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importance of sequencing a matched parental control sample to identify “private” 
variants in individual iPS clones. Compared to its own parental line, each iPS clone 
contained a range of 176-701 SNVs (Figure 6A), 3-19 of which were within gene coding 
regions (Figure 6B, Table 3). Plotting the location of each SNV within the genome 
suggested that most variants are randomly distributed (Figure 7); a chi-squared analysis 
of the spatial distribution of mutations confirmed that the distribution was random. 
 
The digital readcounts provided by whole genome sequencing allows for calculation of 
variant allele frequency for all SNVs. Variant allele frequency plots of all SNVs for all 10 
iPS lines revealed that the variant frequency is distributed around a mean of ~50% 
(Figure 8), and that the distribution is consistent with a binomial distribution.  This data 
suggests that the SNVs are probably heterozygous, and present in virtually all the cells in 
the iPS sample tested.  Further, the presence of a single dominant clone in each sample 
suggests that all of the mutations arose at or before the time of reprogramming. 
 
Mutational consequences of iPS SNVs 
All of the SNVs reported within coding regions were secondarily validated by exome 
sequencing for experiments 1 and 2, or by 454 sequencing of PCR amplified regions for 
experiment 3 (Table 3). Each iPS genome contained an average of 10 coding region 
SNVs per genome (including missense, nonsense, splice site and silent mutations). In 
addition to the coding mutations, each iPS clone contained 186-679 predicted SNVs in 
non-coding regions of the genome (Figure 6). For the three iPS clones in experiments 1 
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and 2, all of the SNVs were unique to each genome, and there was no overlap among the 
variants detected in each experiment. 
 
Among the 336-409 total SNVs detected in each iPS genome in experiment 3, however,  
there were 162 validated SNVs (5 within coding regions) that were detected in all four 
iPS lines (Figure 9). We tested for the 5 common coding region SNVs in two additional 
iPS lines generated from the same experiment, and both were heterozygous for all 5 
variants (data not shown). To determine whether this set of common variants was not a 
consequence of reprogramming fibroblasts derived from the GusB -/- strain, we did a 
second reprogramming experiment using GusB -/- tail tip fibroblasts (TTFs) from a 
different mouse. We screened 10 individual iPS clones from the second reprogramming 
experiment for two of the shared mutations (Apaf1 G16A and Sbno2 A3783G), and did 
not detect either SNV in any clone (Figure 10).  
 
To further confirm that the four iPS clones from experiment 3 had a common set of 
genetic variants, we also searched for common indels and structural variants. Somatic 
indel prediction analysis identified 32 variants that were present in all four iPS clones 
(Table 4); none had a translational effect. We also identified a common amplified region 
of ~130 kilobases on chromosome X that was present in all four iPS clones, but not 
detected in the parental MEFs (Figure 11). Two genes fall within this region, Mug2 (a 
protease inhibitor) and Gm10319 (a predicted gene).  
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The identification of a large set of shared genetic variants strongly suggests that all four 
of these iPS lines arose from a set of “founder” MEFs containing the same variants.  
However, none of the common SNVs were detected in the parental MEFs even with deep 
readcounts (which is limited by an error rate of 1%), suggesting that the founding 
population represents fewer than 1% of the total cells in the MEF pool. In an attempt to 
detect these rare cells, we took advantage of novel StuI restriction sites created by two of 
the common coding region SNVs (i.e. Apaf1 G16A and Sbno2 A3783G). We amplified 
regions containing these variants with PCR, and then cloned pools of these amplicons 
into the pCR2.1 vector (Invitrogen, Carlsbad, CA). DNA derived from pools containing 
hundreds of unique amplicons were then digested with StuI, and the digestion products 
were detected by Southern blot analysis. Figure 12 shows representative blots of the 
Apaf1 and Sbno2 analyses. DNA from a pool of clones from one of the iPS cell lines 
reveals that ~50% of the starting DNA is digested by StuI.  However, most pools of 
clones derived from the MEFs reveal no digestion products; only occasional pools 
contain very small amounts of the digestions products, suggesting that no more than one 
or two plasmids within the pool contains the variant allele. Table 5 shows the total 
number of MEF pools screened for each variant, and the total number of clones screened 
in this pool. 
 
Although these results are semiquantitative, it is clear that less than 1 MEF cell in 1,000 
contains the common variants detected in all of the iPS clones.  Further, these results 
make it extremely unlikely that the common variants arose after reprogramming event. 
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In addition to the common variants in the iPS clones of experiment 3, there were also 
299-535 unique SNVs in each of the clones (Figure 9). To assess whether the private 
variants were acquired before or after the reprogramming event, we compared the variant 
allele frequencies of common SNVs vs. private SNVs. The common variants show the 
same variant allele frequency distribution seen for the other experiments in Figure 8. 
While the majority of the private SNVs are also present in ~50% of reads, clones 1, 2 and 
6 have a subset of variants present in only 20-30% of reads, suggesting presence of a 
subclone (Figure 13).  
 
Other than the common variants in experiment 3, there was no overlap in the genes 
containing SNVs among the three experiments. We also compared all of the genes with 
coding region SNVs in our dataset to that of Gore, et al. where the exomes of 23 human 
iPS lines were sequenced.  A single gene, ATM/Atm, contained an SNV in both datasets: 
in our study, clone 5 from experiment 1 contains a splice site mutation at the 5’ end of 
intron 23; one of the 22 human iPS clones contained a nonsynonymous SNV in ATM 
(X444Y) [37]. 
 
Gore, et al. also reported their human iPS clones displayed a significant enrichment of 
mutations in genes found in the COSMIC database [37]. We therefore examined the 89 
unique genes with coding region SNVs in our 10 iPS clones, and found that that 36 
(40.4%) were in the COSMIC database  (Table 3). We also searched the COSMIC 
database for the 247 genes with homozygous variants in the three parental mice used in 
this study (compared to the B6 reference genome); 36.1% of these genes are likewise in 
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COSMIC, a value that is not significantly different from that of the iPS clones 
(p=0.5733).  
 
We also performed a pathway analysis using the MuSiC suite to test for significantly 
mutated genes (SMGs), and common pathways that might be affected by mutations 
among the 10 clones.  The only SMGs were the 4 common missense variants identified in 
experiment 3.  A total of 50 pathways contained genes that were mutated (Table 6). Only 
13 of these had a P-value of less than 0.05; all included one of the common variants from 
experiment 3. There were no pathways with hits in all 10 clones. This analysis suggests 
that in these 10 iPS lines, there is no common pathway that contains mutations that 
faciliate reprogramming. 
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Discussion 
In this study, we have defined the genetic landscape of 10 independent murine iPS cell 
lines by whole genome sequencing.  A polycistronic lentivirus was used for 
reprogramming so that virus integration sites could provide definitive marks for each 
clone; the absence of overlapping insertion sites shows that insertional mutagenesis does 
not target specific endogenous loci for successful reprogramming. In the first two 
experiments, we identified several hundred SNVs in each individual clone (with an 
average of 11 in coding sequences), but found no overlap among the mutations in any of 
the clones. In the third experiment, however, we identified a subset of common variants 
in all four iPS clones, as well as a set of “private” variants in each.  Using genomic DNA 
from the parental MEFs used to create these clones, we were able to detect two of the 
common mutations at a very low frequency, demonstrating that rare “founder” cells 
within the total MEF population contained these mutations (i.e. they did not arise during 
reprogramming or expansion of the cells); this suggests that one or more the common 
mutations may have contributed to the extraordinary “fitness” of these cells for 
reprogramming.  Using the mutational profiles and variant allele frequencies from all 10 
clones, we were able estimate the timing of SNVs associated with reprogramming. Our 
data suggests that many SNVs may occur at or before the time of reprogramming, and 
that some may occur during expansion of the iPS clones in culture. Regardless, all iPS 
cell lines contain hundreds of mutations. Although most are probably functionally 
irrelevant (reflecting random genetic events in the starting cells that are “captured” by the 
process of cloning individual cells), some may contribute directly to reprogramming 
fitness.  
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The use of whole genome sequencing, with assessment of the variant allele frequencies of 
hundreds of mutations, is a very powerful tool that has allowed us to begin to assess 
whether the mutations detected in iPS clones are caused by reprogramming (i.e. the 
mutations are new), or whether they simply represent the genetic “signature” of the cell 
that was reprogrammed (i.e. the mutations were present before reprogramming, and were 
“captured” by virtue of the cloning event).   In the first two experiments, this issue could 
not be resolved.  All SNVs in all six clones were unique and distributed randomly in the 
genome, with variant allele frequencies of ~50%, suggesting that all the SNVs were 
heterozygous, and present in all the iPS cells.  Three scenarios could explain these 
results: 1) the SNVs preexisted in the cell that was reprogrammed, and reflect the 
background mutations that were present in that cell, or 2) the variants all arose in a 
“burst” of mutational activity at the time of reprogramming, but they were not relevant 
for positive selection (which was provided by the reprogramming factors), or 3) the 
SNVs all arose in a burst of mutational activity after reprogramming; one or more 
mutations was important for selection, and the entire group of mutations was “captured” 
as a set in the iPS clone.  Based on our knowledge of the background rate of mutations in 
somatic cells [54, Ley, et al., manuscript in preparation], and the large numbers of 
mutations detected in each clone, we suspect that the latter two scenarios are unlikely. 
Regardless, they cannot be ruled out with the data in the first two experiments. 
 
However, in the third experiment, we detected a very large set of common mutations in 
all four iPS clones that were sequenced, including SNVs, indels, and a structural variant; 
	   108	  
we detected 5/5 coding SNVs tested in two other iPS clones generated in the same 
experiment (importantly, these common variants were not detected in 10 iPS clones 
derived from another reprogramming experiment, using fibroblasts from an independent 
GusB deficient mouse, i.e. they are not related to the mouse strain itself).  Using 
techniques that could detect point mutations in rare cells, we were able to detect two of 
the common mutations at a very low frequency in the starting MEF pool, suggesting that 
fewer than 1 MEF in 1000 contained the common mutation set.  Since all six iPS lines 
obtained from the starting pool of 300,000 cells contained the same set of mutations, it is 
clear that these cells were much more likely to undergo reprogramming than the 
‘average’ MEF in the pool.  Although is not yet clear which of the mutations might have 
been responsible, some candidates are attractive (e.g. the Apaf1 mutation may alter a 
threshold for apoptosis during reprogramming stress).  Sequencing the genomes of large 
numbers of iPS clones from independent pools of starting cells may allow for the 
identification of recurring mutations (or pathways) in iPS clones; these data may help to 
elucidate the genetic barriers to reprogramming, and provide novel approaches for 
improving the efficiency of the process. 
 
Some data pertinent to this idea is already available. Gore, et al. performed whole exome 
sequencing on 22 human iPS lines that were created with a variety of reprogramming 
approaches (including 4-factor retroviral and lentiviral, 3-factor retroviral, episomal 
vector and messenger RNA).  Among this set, 7 pairs of lines were generated from the 
same parental cells; in 3/7 pairs, the authors detected common SNVs (1-3 common 
mutations were detected, along with a few private mutations in each of the members of 
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the pair).  None of these mutations was detected in other human iPS clones, and none 
were detected in our common set of mutations.  Even though exome sequencing of iPS 
clone pairs should be less sensitive than whole genome sequencing of iPS clone trios, it is 
striking that 4 out of 10 sets of iPS clones derived from the same parental cells have 
shown common variants; this is not a rare event.  Although the significance of these 
mutations is unknown, they are clearly not providing an overall selective advantage for 
cells before they are reprogrammed (since they are rare in the starting population).  
However, one or more of the common mutations would be expected to be capable of 
cooperating with reprogramming factors, raising a concern that cells derived from these 
iPS clones may be different from those derived from somatic cells without cooperating 
mutations.  
 
As noted above, we evaluated variant allele frequencies in the iPS clones to help 
understand clonality and the timing of mutational events.  The variant allele frequencies 
of all 10 clones averaged 50%, and fit a binomial distribution (Figure 8), suggesting that 
most variants are heterozygous, and present in virtually all cells in the sample.   In 
experiment 3, we further examined the variant allele frequencies of the common vs. 
private mutations in each clone (Figure 13).   The common variants occurred prior to 
reprogramming, and have an average variant allele frequency of 50%, as expected.  The 
private variants also have a major peak of variant allele frequencies at 50%, but three 
clones (1, 2, and 6) also had a minor, secondary peak at 20-30%.  These data suggest that 
the private mutations in each clone must have arisen after the common mutations, but still 
occurred at or before the time of reprogramming (since most variants are present in all 
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cells). However, the minor peak of variant allele frequency in three of the clones suggests 
that a third set of mutations arose in a subset of cells after reprogramming.  Some of the 
mutations present in these subclones must allow for positive selection of these cells, 
allowing for their detection in the total pool of cells.  Since we sampled clones at a single 
time in their existence, we do not know whether these late subclones are becoming 
dominant, are failing, or are stable; serial sampling would be required to resolve this 
question. However, these results do suggest that mutations in iPS clones may evolve with 
serial passaging, as previously suggested by Laurent, et al. [55]. 
 
Based on this information, we propose a model of how mutations are acquired during iPS 
cell development (Figure 14).  Most of the time, individual iPS clones arise from unique 
cells within the transduced parental cell population. Each cell has a unique set of pre-
existing background mutations, which are “captured” by the expansion and cloning of 
single cells with reprogramming (Panel A). However, there are some instances where 
pre-existing mutations are relevant for a cell’s reprogramming susceptibility. These 
“super fit” cells are much more likely to be reprogrammed and detected as iPS clones, 
since their background mutations must cooperate with reprogramming factors (Panel B). 
Between the time when the fitness mutations are acquired and the reprogramming event 
occurs, additional private mutations are acquired (which may or may not further increase 
reprogramming efficiency).   Finally, additional mutations can be acquired after 
reprogramming that provide additional selective pressure for the outgrowth of subclones. 
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Although one or more of the common mutations found in some iPS clones are very likely 
to be relevant for reprogramming, it is less clear whether the private mutations are.  The 
private mutations are randomly distributed in genome space, which explains why so few 
fall in coding sequences (which comprise about 1% of the genome).  The number of 
mutations detected in each iPS exome is about the same, regardless of whether the 
starting cells are from disease models, normal mice, or human volunteers.  The method of 
reprogramming (even with non-integrating methods) did not affect total numbers of 
exonic mutations detected in the Gore, et al. study, and the numbers detected in our 
murine iPS clones were similar to theirs.  Although Gore, et al. suggested that iPS 
mutations were enriched in cancer-associated genes in their human iPS clones, our study 
revealed that the percentage of exonic mutations found in the COSMIC database is the 
same for our iPS clones and the random background mutations that were detected in the 
three different B6 mice used to generate the clones (which arise because of genetic drift 
within inbred mice; p=0.5733).   All in all, these additional observations support the 
model proposed above, where most of the mutations detected in iPS clones probably 
occurred before reprogramming, and are benign, irrelevant events that reflect the 
mutational history of the cell that was cloned in the reprogramming process. 
 
Although there is a range of reprogramming fitness within a given population of somatic 
cells, these data show that it may be in part based on random genetic variants that occur 
within individual somatic cells, suggesting several important caveats for the field of 
somatic cell reprogramming.  In the act of cloning individual somatic cells, background 
genetic variants will invariably be ‘captured’ by the cloning act itself, regardless of the 
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strategy used to induce reprogramming.  If fitness mutations are present in rare somatic 
cells, they could potentially cooperate with reprogramming factors, regardless of how the 
factors are delivered (stably integrated viruses, transiently expressed plasmids, mRNAs, 
or proteins).  Although this may have important consequences for the use of iPS clones in 
therapeutic settings, the sequencing of large numbers of iPS clones may also provide a 
new strategy for identifying genes that represent barriers for reprogramming, and suggest 
approaches to safely overcome them. Perhaps most importantly, these results strongly 
suggest that reprogramming is not a mutagenic event per se, and that knowledge gained 
from sequencing iPS cell genomes may help to refine the process and make it safer for 
therapeutic purposes. 
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Figure Legends 
Figure 3-1. Unsupervised cluster analysis of Mouse Exon 1.0 ST array data.  
Each sample had two independent RNA samples (the second B6 Blu ES cell RNA sample 
was too low quality to put on the array). Samples are indicated below the heatmap. The 
MEFs segregate together and the iPS clones segregate with the ES cells. 
 
Figure 3-2. Bisulfite sequencing of the Oct4 and Nanog promoters.  
Genomic DNA from two separate preparations of MPS VII MEFs, B6 neo/hygro resistant 
(N/H) MEFs, MPS VII ES cells, B6 Blu ES cells and all 4 iPS lines was bisulfite treated 
with the Zymo EZ Methylation-Direct kit (D5020). The promoter regions of Oct4 (Panel 
A) and Nanog (Panel B) were then amplified using primers specific for bisulfite converted 
DNA (to select for fully converted DNA). Purified PCR products were directly analyzed by 
454 sequencing. Using this method we were able to get sequence for >1000 PCR products 
of each promoter. The conversion rate was calculated as (# non CpG ‘C’ nucleotides 
converted to ‘T’/ total # non CpG ‘C’ nucleotides) and was > 99% for each locus in each 
sample.  Methylation at each position was then calculated as the “% Methylated Reads” (# 
reads with ‘C’ at CpG position/total # reads). 
 
Figure 3-3. Cystic teratoma histology.  
1 million ES or iPS cells were injected into the right hind flank of NOD/SCID/γ chain -/- 
mice. Teratomas were harvested 4-6 weeks later. All 3 germ layers were identified in each 
of the teratomas. Images are H&E stained slides with magnification noted. 
 
Figure 3-4. OSK lentivirus insertion sites prove iPS clonality 
A. Insertion sites of OSK lentivirus for each clone indicated on a graphic representation of 
the 20 mouse chromosomes. Each iPS line had 1-5 insertion sites. Experiment 1 in green, 
experiment 2 in red and experiment 3 in blue. B. Mouse Exon 1.0ST expression data (same 
samples from Figure 1) for the nearest neighbor genes of each of the insertion sites in the 
experiment 3 clones. 
 
Figure 3-5. Homozygous SNVs in fibroblast lines compared to B6 reference genome.  
A. Total SNVs B. SNVs within coding regions 
 
Figure 3-6. SNVs in iPS clones compared to parental fibroblast lines.  
A. Total SNVs B. SNVs within coding regions. 
 
Figure 3-7. Circos plots illustrating genomic distribution of SNVs in each iPS clone 
The genome of each iPS clone is illustrated as a circular diagram of the 20 chromosomes. 
Each red tick mark represents an individual SNV. 
 
Figure 3-8. Variant allele frequency plots of iPS clones. 
For each iPS clone, the variant allele frequency and read count depth of every SNV is 
plotted, the majority of all SNVs are present in half of the reads. A cutoff of 30% variant 
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allele frequency was used to eliminate reads from any potential contaminating feeder MEFs 
(which would have been derived from a different mouse). 
 
Figure 3-9. Common and private mutations in the 4 iPS clones from experiment 3.  
A. Coding region SNVs B. Non-coding region SNVs 
 
Figure 3-10. Analysis for common SNVs in an additional MPSVII iPS clones from an 
independent reprogramming event.  
MPSVII-derived TTFs were transduced with the OSK lentivirus and gDNA was prepared 
from 10 iPS clones. Apaf1 (Panel A) and Sbno2 (Panel B) regions were amplified from 
each clone along with iPS clone #1 from experiment 3 and iPS clone #1 from experiment 2 
as positive and negative controls, respectively. PCR products underwent Sanger sequencing 
to determine presence of the variant allele. Each plot shows the variant bp +/- 3 bp on 
either side. All 10 clones were WT for both loci. 
 
Figure 3-11. Common structural variant in the 4 iPS clones from experiment 3. 
A single structural variant was identified in all 4 iPS clones from experiment 3 spanning 
~130,000 kb on chromosome 6. 
 
Figure 3-12: Detection of common variants in rare proportion of parental MEF 
population.  
The Apaf1 and Sbno2 loci were amplified from the MPSVII MEF population from 
experiment 3 followed by cloning into the pCR2.1 vector. Clones were counted and pooled 
and gDNA was prepared from these clone pools. Each pool was then digested with StuI 
and EcoRI to detect the novel StuI sites generated by the Apaf1 G16A and Sbno2 A3783G 
variants. Digestion products were run on 5% polyacrylamide gels, transferred to 
nitrocellulose and analyzed by Southern blot for digested bands. Expected band lengths are 
indicated below the blot images. * indicates the variant-specific digestion products. 
Figure 3-14. Variant allele frequency of private SNVs compared to common SNVs. p-
values are listed at the top of the figure. 
 
Figure 13. Comparison of common vs private variant allele frequencies  
Variant allele frequencies for the common and private SNVs from the clones of experiment 
3 were plotted and compared. The common SNVs are present in ~50% of reads, suggesting 
heterozygosity. The second, smaller peak in clones 1, 2 and 6 represents a subclone that 
arose after reprogramming. 
 
Figure 14. Model of selection in iPS reprogramming. 
A. In most caes, each cell has a unique set of pre-existing background mutations, which 
are “captured” by the expansion and cloning of single cells with reprogramming. B.  In 
some cases, pre-existing mutations render a cell “super fit” for reprogramming. Private 
mutations can be acquired throughout the culture and reprogramming process: 1) between 
the time when the fitness mutations are acquired and the reprogramming event occurs, 2) 
at the time of reprogramming 3) after reprogramming. Mutations arising post-
reprogramming can provide additional selective pressure for the outgrowth of subclones. 
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Table 3-1. Generation and characterization of iPS clones 
 
 
 
  
SSEA1%+ Nanog%+ Oct%3/4+
Clone%4 e13.5 6 17 29%(9) Yes Yes Yes Yes Yes
Clone%5 e13.5 6 17 29%(9) Yes Yes Yes Yes Yes
Clone%9 e13.5 6 17 29%(9) Yes Yes Yes Yes Yes
Clone%1 65d 20 26 16%(4) Yes Yes Yes Yes Yes
Clone%2 65d 20 26 16%(4) Yes Yes Yes Yes Yes
Clone%3 65d 20 26 16%(4) Yes Yes Yes Yes Yes
Clone%1 e13.5 6 17 24%(8) Yes Yes Yes Yes Yes
Clone%2 e13.5 6 17 24%(8) Yes Yes Yes Yes Yes
Clone%5 e13.5 6 17 24%(8) Yes Yes Yes Yes Yes
Clone%6 e13.5 6 17 24%(8) Yes Yes Yes Yes Yes
ESBlike%
morphology
Alkaline%
phosphatase%
staining%
positive
Flow%cytometric%staining
1%%%%%%%%%%%%%%%%%%%%%% %
(WT%B6%
MEF)
%2%%%%%%%%%%%%%%%%%%%%%%%%
(WT%B6%TTF)
Day%postB
transduction%
colony%was%
picked
Days%in%
culture%
from%clone%
picking%to%
gDNA%prep%
(#%passages)
3%%%%%%%%%%%%%%%%%%%%%%
(GusBB/B%B6%
MEF)
Experiment%
(Parental%
Cells) Clone
Age%of%
mouse
Days%in%
Culture%PreB
transduction
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Table 3-2. Whole genome sequencing coverage and lentivirus insertion sites of all 10 
iPS clones 
 
 
 
  
Experiment:Clone
WGS1
Haploid1
Coverage
OSK1
Coverage
#1of1Unique1
OSK1
integrations
Integration1
Positions
1:WT1MEF 55.178 n/a n/a n/a
1:4 45.689 105.175 3
6:116062660;1
11:54261983;1
17:29179146
1:5 55.191 176.645 4
7:20201630;1
9:34109963;1
15:8307932;1
16:36841079
1:9 57.668 104.485 2 12:56888952;1
X:82219170
1:WT1TTF 22.727 n/a n/a n/a
2:1 26.56 148.404 1 X:23294264
2:2 24.377 66.531 2 7:102410141;1
9:41255493
2:3 30.255 75.629 5
3:65184739;1
7:66559629;1
10:30896454;1
12:70688422;1
14:97803433
3:GusBS/S1MEF 17.877 n/a n/a n/a
3:1 28.896 20.387 2 5:16530376;1
9:72205724
3:2 23.958 12.279 2 4:139018701;1
14:84892429
3:5 19.591 12.603 1 14:6229265
3:6 22.005 13.74 2 12:99479785;1
16:38231164
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Table 3-3. Validated coding region SNVs  
 
 
Reference'
Reads
Variant'
Reads
Variant'
Frequency
1:4 1:52720233 G1697C P566R Mfsd6 YES NO 96 76 0.44186047
1:4 13:11886861 A2419G F807L Ryr2 YES YES 87 67 0.43506494
1:4 14:50760000 G313A H105Y Olfr728 NO NO 90 95 0.51351351
1:4 7:104810281 A1707C K569N Rsf1 YES NO 129 129 0.5
1:5 11:65885466 C5524T V1842M Dnahc9 YES NO 207 105 0.33653846
1:5 11:71580404 C532T R178W Wscd1 NO NO 82 55 0.40145985
1:5 19:6531496 G4460A G1487D Nrxn2 YES NO 55 66 0.54545455
1:5 2:86195991 G547A P183S Olfr1056 NO NO 171 129 0.43
1:5 7:27457861 T1177C S393G Cyp2b23 NO NO 333 252 0.43076923
1:5 9:53303955 A3585(+2)G e23+2 Atm YES YES 69 67 0.49264706
1:9 18:66158326 C287A S96I Lman1 NO YES 287 154 0.34920635
1:9 19:10330864 C1135T E379K Dagla YES NO 255 144 0.36090226
1:9 7:4960568 T552C G184 Fiz1 NO NO 292 139 0.3225058
2:1 14:51135247 G367A A123T Olfr742 NO NO 387 407 0.51259446
2:1 17:46662058 A3610T S1204T Cul9 YES NO 34 23 0.40350877
2:1 18:4349082 T233G Y78S Map3k8 YES YES 62 68 0.52307692
2:1 2:119346067 G1448C A483G Exd1 YES NO 151 132 0.4664311
2:1 2:66522305 C3181T V1061M Scn7a YES NO 40 35 0.46666667
2:1 2:86829071 T261G K87N Olfr1101 NO NO 68 74 0.52112676
2:1 4:115164785 G682A R228C Cyp4a14 NO NO 45 31 0.40789474
2:1 6:119987197 T454C T152A Wnk1 YES YES 93 1314 0.93323864
2:1 6:119986949 T702C T234 Wnk1 NO YES 183 1421 0.88591022
2:1 6:138314487 T414A E138D Lmo3 NO NO 13 17 0.56666667
2:1 7:132816231 T2029C T677A Gtf3c1 YES NO 275 270 0.49541284
2:1 4:43646587 C858T L286 Npr2 NO YES 56 45 0.44554455
2:1 9:56746380 T6667C L2223 Cspg4 NO NO 67 67 0.5
2:1 4:15828065 A507(\2)G e8\2 Calb1 YES NO 86 92 0.51685393
2:2 1:16450468 C307A A103S Stau2 NO NO 48 40 0.45454545
2:2 11:73525754 C2021T T674I Zfp735 NO NO ND ND ND
2:2 13:66953683 A324C C108W Zfp640 NO NO 5 3 0.375
2:2 3:113266509 G598A H200Y Amy1 NO NO 91 80 0.46783626
2:2 5:137589316 C1215A K405N Trim56 YES NO 137 127 0.48106061
2:2 6:30504261 C879G S293R Cpa2 YES NO 45 42 0.48275862
2:2 7:112276751 T169C I57V ENSMUSG00000059768 NO NO 30 18 0.375
2:2 7:12342475 C870G I290M V1rg2 NO NO 138 113 0.4501992
2:2 7:148129017 C389A T130K Athl1 YES NO 128 148 0.53623188
2:2 10:85342131 G735A G245 Pwp1 NO NO 26 21 0.44680851
2:2 15:75696200 C696A L232 Gsdmd NO NO 94 74 0.44047619
2:2 2:163384795 C597A V199 Hnf4a NO YES 63 27 0.3
2:3 1:34876755 T251A Y84F Fam168b NO NO 36 27 0.42857143
2:3 10:62780068 G3006T M1002I Herc4 YES NO 43 47 0.52222222
2:3 11:117891399 C190G P64A ENSMUSG00000061395 NO NO 16 17 0.51515152
2:3 11:94420228 C1679G S560T Acsf2 NO NO 47 32 0.40506329
2:3 13:81030887 C1172A P391Q Arrdc3 YES NO 30 25 0.45454545
2:3 15:44377040 T7376A V2459E Pkhd1l1 YES NO 12 19 0.61290323
2:3 16:18399813 G1651A A551T Arvcf YES NO 13 10 0.43478261
2:3 2:76647962 T41358A Q13786H Ttn YES YES 39 28 0.41791045
2:3 5:20759811 C1455A D485E Pion YES NO 52 42 0.44680851
2:3 5:26445213 G375T D125E ENSMUSG00000067698 NO NO 1034 252 0.1958042
2:3 7:51884733 G2957C A986G Myh14 NO YES 13 8 0.38095238
2:3 7:99565750 G1895A R632H Dlg2 YES NO 65 71 0.52205882
2:3 7:10574295 C400A E134* Vmn2r49 NO NO 318 285 0.47263682
2:3 10:88446510 T1728A L576 Ano4 NO NO 37 42 0.53164557
2:3 16:88774114 G282T I94 2310057N15Rik NO NO 25 27 0.51923077
2:3 17:72056421 C1623A V541 Fam179a NO NO 47 58 0.55238095
2:3 2:85448358 T708C K236 Olfr1000 NO NO 76 66 0.46478873
2:3 4:151744896 C2640T P880 Chd5 NO NO 23 30 0.56603774
2:3 5:63121879 C1362T T454 Arap2 NO NO 35 35 0.5
2:3 X:121244726 C1516G A506P Vmn2r121 NO NO 127 76 0.37438424
2:3 X:88880865 G1083T K361N LOC629542 NO NO 47 37 0.44047619
2:3 X:137606686 G4303C L1435V Col4a6 YES YES 16 11 0.40740741
Found'in'
OMIM?
Variant'ValidationExperiment:
Clone Position Mutation
Translation
al'Effect Gene
Mutated'in'
COSMIC?
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Reference'
Reads
Variant'
Reads
Variant'
Frequency
3:1 1:99079629 G625A A209T EG634331 NO NO 1093 385 0.26048714
3:1 6:119218294 C944T A315V Cacna2d4 YES YES 305 904 0.74772539
3:1 10:90542754 G16A R6C Apaf1 YES NO 947 533 0.36013514
3:1 14:27488308 C731T R244Q Pde12 NO NO 2822 1818 0.39181034
3:1 10:79520428 A3783G A1261 Sbno2 NO NO 1438 1640 0.53281352
3:1 2:69374051 C760T D254N Lrp2 YES YES 141 475 0.7711039
3:1 5:72630517 G666T Q222H Atp10d YES NO 594 2171 0.78517179
3:1 7:97388761 T598A T200S Ccdc83 NO NO 1370 1048 0.43341605
3:1 13:64369144 C5T T2M 1810034E14Rik NO NO 1087 1100 0.50297211
3:1 13:89747651 C968A P323Q Hapln1 YES NO 226 441 0.66116942
3:1 2:76716141 C23955A G7985 Ttn YES YES 774 732 0.48605578
3:2 1:99079629 G625A A209T EG634331 NO NO 305 278 0.47684391
3:2 6:119218294 C944T A315V Cacna2d4 YES YES 616 358 0.36755647
3:2 10:90542754 G16A R6C Apaf1 YES NO 800 308 0.27797834
3:2 14:27488308 C731T R244Q Pde12 NO NO 2030 1800 0.46997389
3:2 10:79520428 A3783G A1261 Sbno2 NO NO 1990 2106 0.51416016
3:2 2:164887834 G100A D34N Cd40 YES YES 2006 2064 0.50712531
3:2 5:122919663 A791G I264T Atp2a2 YES YES 1475 1531 0.5093147
3:2 7:47332084 T789G E263D Mrgpra5 NO NO 432 399 0.4801444
3:2 8:106854405 C496A L166I Cmtm2b NO NO 987 1116 0.53067047
3:2 17:37436493 C873T L291 Olfr101 NO NO 423 212 0.33385827
3:5 1:99079629 G625A A209T EG634331 NO NO 938 1004 0.51699279
3:5 6:119218294 C944T A315V Cacna2d4 YES YES 603 487 0.44678899
3:5 10:90542754 G16A R6C Apaf1 YES NO 485 291 0.375
3:5 14:27488308 C731T R244Q Pde12 NO NO 2046 2266 0.5255102
3:5 10:79520428 A3783G A1261 Sbno2 NO NO 1894 2310 0.54947669
3:5 6:64013952 A883C S295R Grid2 YES NO 663 975 0.5952381
3:5 17:32494082 G2342C A781G Wiz NO NO 1643 1387 0.45775578
3:5 17:34174154 G1352A R451Q Rxrb YES NO 1341 910 0.40426477
3:5 5:97636472 A215C *72S LOC100040598 NO NO 805 805 0.5
3:5 17:33140786 C1293T R431 Zfp952 NO NO 1246 814 0.39514563
3:5 X:65963791 A1305G Q435 Fmr1 NO YES 324 278 0.46179402
3:6 1:99079629 G625A A209T EG634331 NO NO 1324 249 0.15829625
3:6 6:119218294 C944T A315V Cacna2d4 YES YES 751 367 0.32826476
3:6 10:90542754 G16A R6C Apaf1 YES NO 802 451 0.35993615
3:6 14:27488308 C731T R244Q Pde12 NO NO 2054 1825 0.47048208
3:6 10:79520428 A3783G A1261 Sbno2 NO NO 2017 1940 0.49027041
3:6 1:108948259 G89A P30L Serpinb3a NO NO 1084 1408 0.56500803
3:6 15:101612057 T755G K252T Krt72 YES NO 707 1261 0.64075203
3:6 8:97894729 C1425T F475 Mmp15 NO NO 1101 271 0.19752187
3:6 13:73819506 G1638A F546 Slc6a19 NO YES 2032 491 0.19460959
3:6 17:25608777 G111A T37 Tekt4 NO NO 2798 2314 0.45266041
Mutated'in'
COSMIC?
Found'in'
OMIM?
Variant'ValidationExperiment:
Clone Position Mutation
Translation
al'Effect Gene
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Table 3-4. Common indels in all 4 Experiment 3 iPS clones 
 
 
 
  
Start%Position Indel%Type Reference Variant Gene Amino%Acid%Change
1:151199053 DEL A 0 None%Annotated n/a
1:186196114 DEL T 0 None%Annotated n/a
3:48132682 INS 0 AT None%Annotated n/a
10:108602704 DEL TTT 0 None%Annotated n/a
10:113653029 INS 0 A None%Annotated n/a
14:62764104 DEL TGCTTCTGTAGACG 0 None%Annotated n/a
14:38669259 INS 0 C None%Annotated n/a
14:83683846 INS 0 A None%Annotated n/a
15:50209877 DEL TCT 0 None%Annotated n/a
18:3689944 INS 0 T None%Annotated n/a
18:48797211 INS 0 T None%Annotated n/a
X:38193608 DEL G 0 None%Annotated n/a
X:65453524 DEL A 0 None%Annotated n/a
X:94905486 DEL A 0 None%Annotated n/a
3:101347390 DEL A 0 Atp1a1 RNA%gene
10:35418517 DEL A 0 ENSMUSG00000063953 RNA%gene
18:51744954 DEL G 0 ENSMUSG00000077317 RNA%gene
12:34726624 INS 0 T Hdac9 RNA%gene
7:132434793 INS 0 A 4930533L02Rik RNA%gene
17:73797519 DEL C 0 Capn13 RNA%gene
4:43506005 INS 0 TC Car9 RNA%gene
3:89278370 DEL C 0 Kcnn3 RNA%gene
14:58753183 DEL CTC 0 LOC100043554 RNA%gene
16:18686784 INS 0 C LOC622795 RNA%gene
2:148805805 DEL A 0 OTTMUSG00000015744 RNA%gene
16:34605270 INS 0 AC Ropn1 RNA%gene
4:133201025 DEL G 0 Zdhhc18 RNA%gene
7:36203558 INS 0 AC Ccdc123 Intronic:%e9+178
X:72352644 DEL GCGAAT 0 Dkc1 Intronic:%e13+55
4:102178779 DEL C 0 Pde4b Intronic:%e5+132
3:13814071 INS 0 A Ralyl Intronic:%e1+36968
X:98328440 DEL A 0 Snx12 Intronic:%e5W30666
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Table 3-5. Pools tested for presence of Apaf1 and Sbno2 variants 
 
 
  
#"Colonies"
in"Pool
StuI"site"
detected"by"
Southern"
blot?
648 NO
698 NO
662 YES
230 NO
205 NO
149 NO
144 NO
448 NO
192 NO
164 NO
117 NO
98 NO
183 NO
100 NO
431 NO
143 NO
79 NO
100 NO
129 NO
91 NO
157 NO
391 NO
39 NO
49 NO
60 NO
138 NO
192 NO
177 NO
1548 YES
1014 YES
1686 YES
976 YES
141 YES
207 NO
203 NO
169 NO
Apaf1
Sbno2
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Table 3-6. Pathways identified by MUSIC suite as being enriched for in genes with 
SNVs 
 
 
4 5 9 1 2 3 1 2 5 6
Cardiac muscle 
contraction  Ryr2 Cacna2d4 Cacna2d4 Cacna2d4 Cacna2d4 >0.001 >0.001
p53 signaling 
pathway  Atm Apaf1 Apaf1 Apaf1 Apaf1 >0.001 >0.001
Arrhythmogenic 
right ventricular 
cardiomyopathy 
(ARVC)  
Ryr2 Cacna2d4 Cacna2d4, Atp2a2 Cacna2d4 Cacna2d4 >0.001 0.027
Apoptosis  Atm Apaf1 Apaf1 Apaf1 Apaf1 >0.001 0.001
Hypertrophic 
cardiomyopathy 
(HCM)  
Ryr2 Ttn Cacna2d4 Cacna2d4, Atp2a2 Cacna2d4 Cacna2d4 0.001 0.028
Dilated 
cardiomyopathy  Ryr2 Ttn Cacna2d4
Cacna2d4, 
Atp2a2 Cacna2d4 Cacna2d4 0.001 0.086
Amyotrophic 
lateral sclerosis 
(ALS)  
Apaf1 Apaf1 Apaf1 Apaf1 0.001 0.005
Parkinson's 
disease  Apaf1 Apaf1 Apaf1 Apaf1 0.001 0.007
Small cell lung 
cancer  Apaf1 Apaf1 Apaf1, Rxrb Apaf1 0.002 0.033
Alzheimer's 
disease  Apaf1
Apaf1, 
Atp2a2 Apaf1 Apaf1 0.003 0.017
Huntington's 
disease  Apaf1 Apaf1 Apaf1 Apaf1 0.020 0.124
MAPK signaling 
pathway  Map3k8 Cacna2d4 Cacna2d4 Cacna2d4 Cacna2d4 0.043 0.080
Pancreatic 
secretion  Ryr2 Cpa2 Atp2a2 0.065 0.116
PPAR signaling 
pathway  Cyp4a14 Rxrb 0.088 0.249
Toll-like receptor 
signaling pathway  Map3k8 Cd40 0.141 1.000
Viral myocarditis  Myh14 Cd40 0.196 0.508
Cell adhesion 
molecules (CAMs)  Nrxn2 Cd40 0.390 0.742
Calcium signaling 
pathway  Ryr2 Atp2a2 0.513 1.000
Olfactory 
transduction  Olfr1056
Olfr74, 
Olfr1101 0.058 0.304
Asthma Cd40 0.08015 1
Intestinal immune 
network for IgA 
production 
Cd40 0.13049 0.43836
Thyroid cancer Rxrb 0.14428 1
Allograft rejection Cd40 0.14926 1
Primary 
immunodeficiency Cd40 0.1543 1
Autoimmune 
thyroid disease Cd40 0.18528 1
Fatty acid 
metabolism Cyp4a14 0.18542 0.19352
Malaria Cd40 0.20754 1
Starch and 
sucrose 
metabolism 
Amy1 0.21678 0.26482
Hedgehog 
signaling pathway Lrp2 0.22494 0.54339
Carbohydrate 
digestion and 
absorption 
Amy1 0.22762 1
Systemic lupus 
erythematosus Cd40 0.23269 1
Non-small cell 
lung cancer Rxrb 0.23429 1
Retinol 
metabolism Cyp4a14 0.23612 0.36261
Arachidonic acid 
metabolism Cyp4a14 0.24884 0.33438
Adipocytokine 
signaling pathway Rxrb 0.27037 1
Long-term 
depression Grid2 0.32792 1
T cell receptor 
signaling pathway Map3k8 0.34932 1
Protein digestion 
and absorption Cpa2 0.36819 1
Cell cycle Atm 0.42245 0.84099
Toxoplasmosis Cd40 0.42665 1
Protein processing 
in endoplasmic 
reticulum 
Lman1 0.44594 0.94928
Vascular smooth 
muscle 
contraction 
Cyp4a14 0.46016 1
Cytokine-cytokine 
receptor 
interaction 
Cd40 0.46994 0.90212
Ubiquitin mediated 
proteolysis 
Herc4 0.48474 0.99256
Amoebiasis Serpinb3a 0.49434 1
Tight junction Myh14 0.49889 1
Neuroactive ligand-
receptor 
interaction 
Grid2 0.59769 1
Regulation of actin 
cytoskeleton Myh14 0.64666 1
Pathways in 
cancer Rxrb 0.7795 1
FDRPathway
Experiment 1: WT MEF Experiment 2: WT TTF Experiment 3: GusB-/- MEF
p-value
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Figure 3-1 
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Figure 3-2 
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Figure 3-3 
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Figure 3-4 
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Figure 3-5 
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Figure 3-6 
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Figure 3-7 
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Figure 3-8 
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Figure 3-9 
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Figure 3-10 
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Figure 3-11 
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Figure 3-12 
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Figure 3-13 
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Figure 3-14 
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Chapter 4 
 
 
 
Summary and Future Directions 
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Regulation of HOX expression in AML 
In Chapter 2, we explored HOX expression in a diverse group of AML patients and found 
that patients fall into four categories based on HOX expression levels: 1) reprogramming 
translocations with HOX expression below the level of detection – t(8;21) and t(17;15); 
2) reprogramming translocations that express either HOXA (MLL translocations) or 
HOXB (inv(16)) genes, but not both; 3) normal karyotype with high expression of 
HOXA5, A9, A10, B2, B3, and the HOX co-factor MEIS1; 4) normal karyotype with HOX 
expression below the level of detection. While multiple groups have reported HOX 
dysregulation in AML [1-12], we found that this “dysregulation” is actually a canonical 
pattern seen in healthy HSCs. The role of HOX genes in hematopoietic stem cell self-
renewal has been shown in mouse models [13-15]. We hypothesize that capturing the 
normal HOX pattern gives leukemic cells self-renewal capabilities.  
 
Coordinated expression of genes on separate chromosomes suggests the presence of an 
upstream regulator responsible for the HOX pattern seen in AML and healthy HSCs. This 
is supported by the HOX phenotype of MLL (a known regulator of HOX expression) 
mutated AML samples [16-19]. CDX2 is another regulator of HOX expression, which 
has recently been reported to be commonly dysregulated in AML [20].  However, in our 
set of 190 patients, there are 82 with no identified alterations in MLL or CDX2 that 
express HOX genes at high levels, suggesting that a novel upstream regulator(s) is 
affected in these patients. We performed in silico analyses to identify a common 
transcription factor binding motif or an upstream gene whose expression correlated with 
HOXA9 gene expression and found only the subset of expressed HOX genes themselves. 
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This strongly suggests that an autoregulatory loop is responsible for the canonical pattern 
of  HOX gene expression in AML. 
 
To determine if HOX genes are capable of autoregulation, an in vitro reporter system 
could be developed using an YFP cassette under the regulation of the promoter regions of 
various HOX genes. If HOX genes are able to activate their own expression through 
promoter binding, then co-transfection of HOX cDNAs with the correct promoter-YFP 
constructs should induce YFP expression. The higher expression of HOXA9 and HOXB3 
suggests that one or both of them could be the driver of the proposed autoregulatory loop. 
To test this, each cDNA would be co-transfected with promoter-YFP constructs of each 
of the expressed genes (HOXA5, A9, A10, B2, B3 and MEIS1) to see if they can activate 
any of them. Any of the non-expressed HOX genes (the entire HOXC and HOXD cluster 
genes) would serve as important negative controls for this assay. A caveat for this 
experiment is including the appropriate regulatory sequences (which are not known) in 
the cloned promoter regions.  
 
A more physiologic interrogation of HOX function in AML would involve knocking 
down individual HOX genes in primary AML samples. We now have a protocol to 
successfully culture AML samples on a feeder cell layer in the presence of a set of 
cytokines that allows the AML to expand without differentiating. This protocol could be 
used to assess the proliferative capacity of treated samples. Using siRNA targeted to each 
of the expressed HOX genes, single HOX genes could be knocked down to see the effect 
on the growth of HOX expressing AML cells. It could also require knock down of a 
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combination of HOX genes to see a self-renewal defect. These siRNAs should have no 
affect on the self-renewal phenotype of the AML samples that do not express HOX genes 
(t(8;21), t(15;17) and normal karyotype, HOX negative samples).  
 
While these two experiments address the question of HOX autoregulation and its role in 
AML self-renewal, they would not answer how the autoregulatory loop is started. Since 
murine hematopoietic cells do not model the HOX regulation seen in human cells, this 
would require use of an in vitro system. We hypothesize that since the HOX pattern is 
present in HSCs, the initial activator of HOX gene expression would have to be 
expressed at some point before HSCs begin to develop. This HSC progenitor could 
potentially be derived experimentally by growing human ES or iPS cells on mouse OP9 
bone marrow stromal cells. After 7 to 8 days of co-culture with OP9s, iPS cells 
differentiate into hematopoietic progenitors [21]. By harvesting cells on each day of co-
culture and analyzing them on expression arrays, we may be able to determine at what 
stage the HSC HOX genes are first expressed, and search for an upstream regulator 
which is also turned on at that stage or just prior to it. To determine whether any 
identified upstream regulators are sufficient and/or necessary for the HOX expression in 
AML samples, we could return to the AML primary tumor stromal co-culture system. 
Putative regulatory genes could be overexpressed in the HOX negative samples to see 
whether they induce the canonical HOX expression pattern, and/or knocked down in the 
HOX positive samples to see whether they are necessary to maintain the HOX expression 
pattern. 
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In addition to determining the mechanisms underlying HOX expression in AML, our 
results also introduce the question of how the normal karyotype- HOX negative samples 
acquire self-renewal, a necessary step in tumor pathogenesis. HOX is one of many 
pathways that have been indicated in hematopoietic stem cell self-renewal. Mouse 
models have also shown that the Notch signaling pathway is sufficient to induce self-
renewal in HSCs [22]. In unpublished work from our laboratory, we have seen that 
activation of Notch is responsible for self-renewal in murine bone marrow cells that 
express PML-RARA. Hedgehog, Wnt, and FOXO signaling have also been implicated in 
leukemic self-renewal, although all of them have stronger effects in chronic myeloid 
leukemia cells (reviewed in [23]). In data not shown, we analyzed proteins involved in 
the four non-HOX self-renewal pathways to determine whether they are differentially 
expressed in normal karyotype patients with and without HOX expression. The majority 
of genes in these pathways are not expressed in tumors. Those genes that are expressed 
show no difference between the HOX positive and negative normal karyotype samples, 
suggesting that their dysregulation is not responsible for self-renewal in the HOX 
negative samples. It is possible that these samples acquire self-renewal via a pathway that 
is not present in normal hematopoietic cells, but used for self-renewal in the stem cells of 
a different tissue type.  
 
Functional consequences of SNVs in iPS reprogramming 
In Chapter 3, we defined the genetic landscape of 10 iPS clones. In two experiments, we 
found 189 to 701 SNVs in each of six iPS clones. The majority of these variants were 
present in 50% of reads, suggesting that they are heterozygous, and present in all cells in 
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the sample. There are three possibilities for when these SNVs were acquired during the 
reprogramming process: 1) before reprogramming, 2) at the time of reprogramming, 3) 
after reprogramming, where one or more of the mutations would be required for selection 
of the affected cell (the other mutations, although irrelevant for selection, would be 
passengers in the selected cell). Distinguishing between these possibilities is currently not 
experimentally tractable.  Currently, we pick individual clones from the lentiviral OSK 
transduction, and expand them in culture to get enough genomic DNA for whole genome 
sequencing. Laurent, et al. showed that continued passaging of human iPS lines leads to 
increases in copy number variants [24]. We saw a similar result in the private mutations 
in experiment 3, where variant allele frequencies indicated the presence of a subclone in 
3 of 4 iPS lines. If individual cells could be sequenced, we could avoid expansion-related 
variants since they are clearly not required for the reprogramming process. While this 
would allow us to distinguish between the last 2 possibilities for the timing of variant 
acquisition, we would still have to attempt to detect the variants found in reprogrammed 
cells in the parental cells with highly sensitive methods, to distinguish these from variants 
caused by the reprogramming event.  
 
In experiment 3, we obtained a unique and highly informative result, that of common 
variants among all of the iPS lines. Taking our results together with the report by Gore, et 
al. common variants have now been detected in 4 of 10 experiments where more than one 
iPS line has been examined from a single reprogramming event [25]. However, no 
common pathways were identified in the iPS clones from the four experiments with 
common variants. In order to identify reprogramming fitness pathways, many more iPS 
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lines will need to be sequenced. Since a common founder cell was detected in 40% of 
these initial studies, at least 20 additional sets of iPS lines should be studied to verify the 
frequency of this event (with a predicted 8 sets containing a common founder cell).  To 
be confident that common variants are truly the consequence of a shared parental cell 
(and not the rare chance of 2 cells randomly having the same mutation), at least 4 
individual iPS clones should be included in each set of iPS lines, leading to the 
sequencing of 100 genomes. The next decision to be made would be whether to perform 
whole genome sequencing or exome sequencing. Since any pathway identification would 
predominantly utilize variants within coding regions, it is tempting to say that exome 
sequencing would be sufficient. However, alterations in regulatory regions could also 
affect pathways; these variants would be missed by exome sequencing.  By performing 
whole genome sequencing now, variants in currently unidentified regulatory regions and 
unannotated genes could be more relevant in the future, when a fully annotated genome is 
available.  
 
Which iPS clones should be sequenced? Gore, et al. found common variants in iPS lines 
derived with 3- and 4- factor retrovirus and mRNA-mediated reprogramming, proving 
that the delivery method does not affect the selection of a “super fit” cell. In our study we 
used an integrating polycistronic lentivirus so that its integration sites could provide a 
definitive genetic mark for each clone; however, we now know that each iPS clone has a 
large group of “private” mutations, which can also be used to define clonality. Since 
lentiviral transduction with a polycistronic OSK cassette is efficient and clearly has a 
limited number viral integration sites, it would still be a good choice for iPS 
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reprogramming.  Since mouse iPS clones have the same basic findings as human clones, 
since mouse cells are more readily available than human cells, since mouse genome 
sequencing requires less coverage (inbred strains), and mice do not require informed 
consent for whole genome sequencing, a mouse study might be a better choice for the  
large study proposed here. 
 
Once whole genome sequencing has been performed for all 20 sets of iPS genomes, those 
with common variants could be taken forward to identify pathways enriched for in the 
variants. This pathway analysis could provide candidate genes for functional studies. 
These studies would include pathway manipulation (both overexpression and knock 
down) to determine effects on reprogramming efficiency. For example, in experiment 3, 
one of the common variants was Apaf1 R6C; Apaf1 is a key regulator of the apoptotic 
response. If additional common variants in the apoptotic pathway were identified, then 
cells could be transfected with a plasmid encoding Apaf1 R6C (to see if this is a gain-of-
function mutation), and transfected with siRNAs against Apaf1 (to see if it is a loss-of-
function) prior to reprogramming with the OSK lentivirus. If transient manipulation of 
pathways could provide an increase in reprogramming fitness, these results could be used 
to improve the efficiency and safety of iPS reprogramming for therapeutic uses.  
 
Integrating genetics and epigenetics- the transcriptome  
In addition to whole genome sequencing, there are also multiple platforms available for 
assesing the epigenome in iPS cells. As described in Chapter 2, Illumina recently released 
their second generation methylation chip, which can assay 485,577 CpG dinucleotides at 
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single base pair resolution [26]. Methyl-Seq and MeDIP-seq are two additional methods 
to define methylation at single residues, by performing next-generation sequencing of 
fragments of DNA isolated by digestion with methylation-sensitive restriction enzymes, 
or immunoprecipitation with a 5-methylcytosine-specific antibody, respectively [27, 28]. 
Whole genome sequencing of bisulfite-treated DNA (all unmethylated cytosines are 
converted to thymine residues, while methylated cytosines are protected from the 
reaction) allows for a complete, unbiased view of methylation status at all cytosine 
residues in the genome. Although the mapping of a 3-bp genome presents a difficult 
computational issue, this problem has been addressed by the development of mapping 
programs such as BSMAP, but improvements are still required [29].  
 
While these platforms allow for the identification of methylated regions, the biologic 
consequences of methylation are still not completely understood. For example, it has 
been reported that 80% of CpG islands in the genome are not located near genes, and 
most likely have no effect on gene expression [30]. While the dogma of the field has been 
that promoter methylation is associated with promoter silencing [30], many groups have 
now shown the importance of intragenic methylation as a positive regulator of gene 
expression [31-36]. In addition to cytosine methylation, histone modifications also play a 
large role in gene expression [37-39]. Chromatin immunoprecipitation followed by next-
generation sequencing (ChIP-seq) is a technique similar to MeDIP-seq, except that 
antibodies specific to different histone modifications are used instead of antibodies 
specific for 5-methylcytosine residues [40, 41]. Deciphering the meaning of epigenetic 
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differences identified in these comprehensive techniques will be difficult, since the 
linkage of gene expression patterns to epigenetic modifications is far from complete. 
 
One way to help define the consequences of genetic and epigenetic alterations is to 
analyze the transcriptome in parallel with the genome. Next-generation sequencing of 
cDNA (RNA-seq) allows for quantification of expression levels, and identification of 
post-transcriptional modifications in RNA [42-49]. For whole genome sequencing, 
parallel transcriptome analysis allows one to determine whether a mutant allele is 
expressed at equal levels as the wildtype allele, or whether it is associated with RNA 
degradation. Also, if a mutation is identified in a non-expressed gene, it is most likely not 
functionally relevant. For epigenetic studies, having paired RNAseq data will help define 
the transcriptional effects of different epigenetic modifications, clarifying their role in 
gene expression. Comprehensive analysis of the genome, epigenome, and transcriptome 
of cancer cells and iPS clones will allow for a greater understanding of the genetic and 
epigenetic interactions of reprogramming.   
 
in vivo vs. in vitro reprogramming 
 
Comprehensive genomic analysis of AML samples and iPS lines has allowed us to 
identify similarities between these two forms of reprogramming. In both, we have 
determined that though there is a large mutational burden; it is clear that the majority of 
SNVs are passenger mutations that antedated reprogramming. Acquisition of mutations 
occurs over time in all organisms (genetic drift); in Chapter 3, this is illustrated by the 
homozygous variants detected in each of the three mice used to generate fibroblasts. In 
	   149	  
other experiments from our group, we have sequenced individual HSCs from three 
healthy volunteers and seen the accumulation of benign mutations as a function of time 
[Ley, et al. manuscript in preparation]; similarly, there is a strong correlation between 
total mutations and age in the AML samples we have sequenced [Welch, et al. in 
preparation]. In AML, some recurrent mutations are able to act as “drivers” to initiate 
leukemic transformation, such as DNMT3A [50, 51]. The results of our third iPS 
experiment suggest that a similar phenomenon can happen in reprogramming, where one 
or more mutations (generated randomly during the life of the cell) creates a change in a 
cell that makes it “super fit” for reprogramming [25].  In a cancer cell, this kind of 
mutation would be known as a driver, since it can cooperate with progression mutations 
that give the cell a survival and/or proliferative advantage. Sequencing of more iPS 
clones may elucidate recurrent mutations involved in in vitro reprogramming, similar to 
what has been found in AML and other cancers.  
 
Acquisition of self-renewal is a key step in both in vivo and in vitro reprogramming. In 
iPS production, overexpression of Oct4 and Sox2 activates pluripotency pathways in 
somatic cells (Oct4, Sox2 and Nanog. which then act in positive feedback loops to 
maintain self-renewal). The initiation of self-renewal is not as clear-cut in AML. While 
reprogramming translocations have been shown to induce self-renewal in hematopoietic 
cells [52, 53], in Chapter 2 we show that the majority of normal karyotype AML 
overexpress HOX genes in a canonical fashion that mimics that of normal CD34 cells, 
suggesting that these samples acquire self-renewal by “capturing” the normal program in 
the leukemia initiating cell. However, in the AML cases without HOX expression, other 
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known signaling pathways that affect self-renewal are not expressed; the mechanism for 
initiating the self-renewal in these samples remains an unknown. 
 
Both in vivo and in vitro reprogramming lead to generation of cells with limitless growth 
potential. A complete understanding of the similarities between these two processes is 
important for the future therapeutic use of iPS cells. By definition, iPS cells form tumors 
when introduced into immunodeficient mice. In order to use iPS cells for regenerative 
medicine, they will almost certainly need to be differentiated into the desired cell type to 
avoid tumor growth. By understanding the pathways involved in tumorigenesis, it may be 
possible to more safely engineer iPS cells for therapeutic use. The key to using iPS cells 
clinically will be to make them less like tumors, and more like normal, differentiated 
tissue cells. 
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